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ABSTRACT 
 
 
 The transcription factor GATA2 is highly expressed in hematopoietic stem cells 
(HSCs) and is downregulated during differentiation. Overexpression of GATA2 is 
frequently observed in acute myeloid leukemia. In previous studies, enforced expression 
of GATA2 using a MSCV GATA2 retroviral vector blocked differentiation of HSC and 
progenitors without inducing leukemia. We hypothesized that a lower dose of GATA2 
can relieve the HSC block and eventually transform myeloid progenitors into leukemia 
stem cells. To test this hypothesis we generated a MSCV GATA2-ERT vector in which 
nuclear concentration of GATA2 can be regulated by Tamoxifen (TAM). The 
GATA2-ERT protein was confirmed to leak into nucleus of transduced BM cells even in 
the absence of TAM. This low nuclear GATA2-ERT led to enhanced self-renewal of 
myeloid progenitors in vitro and was able to immortalize primary bone marrow (BM) 
cells into IL-3 dependent myeloid cell lines. Continuous GATA2-ERT expression was 
also required for the proliferation of these immortalized lines. Nmyc and HoxA9 mRNA 
were significantly higher in GATA2-ERT immortalized lines compared to control 
immortalized lines. Repression of either Nmyc or Hoxa9 in GATA2-ERT immortalized 
cells impaired their proliferation suggesting that they are potential GATA2 targets 
mediating this effect. 
 
Myeloid expansion and a block in T cell and B cell lineage differentiation was 
observed in transplant recipients of  GATA2-ERT expressing  BM cells without TAM. 
The myeloid expansion occurs after the Granulocyte Monocyte Progenitor (GMP) and 
the lymphoid block occurs after the Common Lymphoid Progenitor (CLP) in transgenic 
mice. Finally using the C352P mutant we showed that myeloid expansion and B 
lymphoid block require DNA binding activity of GATA2-ERT and were not due to the 
dominant negative effect of the cytosolic form of this protein.  
 
We were the first to demonstrate that GATA2 overexpression confers increased 
self-renewal of myeloid progenitors which correlates with increased GATA2 mRNA 
levels frequently observed in human AML patients. We believe that the lower dose of 
GATA2 is critical to this phenotype. Interestingly no myeloid leukemias were observed 
in both the transplant and transgenic animals. 
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CHAPTER 1.    INTRODUCTION 
 
 
Hematopoiesis in the Adult Bone Marrow 
 
Bone marrow (BM) is the primary site of blood production (hematopoiesis) in 
both adult mice and humans. The understanding that the BM is the site of hematopoiesis 
came from studies on radiation injury. In 1945 Hiroshima and Nagasaki atomic bomb 
victims were found to have died of hematopoietic failure.
1
 Later it was shown that a 
similar radiation syndrome in mice could be prevented by BM transplantation.
2-4
 In 1961, 
Till and McCulloch showed that BM cells transplanted into lethally irradiated mice 
formed spleen colonies (CFU-S) which contained a clonal population of myeloerythroid 
cells (granulocytes, macrophages, red cells and megakaryocytes) and cells of lymphoid 
potential.
5-7
 Some cells from these CFU-Ss can form additional CFU-S upon secondary 
transplantation. Till and McCulloch were the first to propose the existence of a 
hematopoietic stem cell (HSC) which can self-renew and differentiate into all blood cell 
types. This led to the search for the Hematopoietic Stem cell in the BM. Between 1988 
and 1992, the Weissman group successfully isolated the murine HSC by enrichment of 
BM cells expressing stem cell markers (Sca-1, c-kit, Thy1.1) and depletion of cells 
expressing the mature “lineage markers” (Gr-1, Mac-1, B220, CD4, CD8,Ter-119 and 
NK1.1).
8,9
 Subsequently it was also shown that all the HSCs of the mouse BM were 
located in this c-kit+, Thy1.1
low
, Lin-, Sca1+ (KTLS) compartment of the BM.
10
 
 
Two models of lineage commitment from the HSC have been proposed so far 
(Figure 1-1). The KTLS cells are a heterogeneous population of multipotent cells with 
different self-renewal capacities.
11
 Within the KTLS cells the Long Term HSCs (LT-
HSCs) are the true HSCs which have the self-renewal capacity for the life-time of the 
organism. The LT-HSCs gives rise to the Short Term HSCs (ST-HSCs) with the self-
renewal capacity of less than 8 weeks and their progeny the Multipotent Progenitors 
(MPPs) with no self-renewal capacity.
12
 In the first model proposed by the Weissman 
group, the ST-HSCs or MPPs gives rise to either a Common Lymphoid Progenitor (CLP) 
or a Common Myeloid Progenitor (CMP) which in turn gives rise to either a 
Granulocyte-Macrophage Progenitor (GMP) or a Megakarocyte-Erythroid Progenitor 
(MEP).
13
 In the alternate model proposed by the Jacobsen group, the MEP is derived 
directly from the ST-HSCs/MPPs and a Lymphoid-Primed Multipotential Progenitor 
(LMPP) gives rise to the CLP and the GMP.
14
 The CLP, GMP, and MEP in turn 
differentiate into respective differentiated cells (CLP: T-cells, B-cells, NK cells; GMP: 
neutrophils, basophils, eosinophil’s, macrophages, mast cells; MEP: Red blood cells, 
platelets) through intermediate progenitor stages. The T-cell progenitors are unique that 
they also retain the ability to differentiate into myeloid cells at early stages.
15,16
 All the 
various stem cells, progenitor cells and mature cells described above can now be isolated 
based on their surface marker expression (Table 1-1). Recently Orkin's group did a 
computational mapping based on multiplex single cell quantitative PCR analysis (280 
cell surface markers) and generated a hierarchy similar to the Jacobsen model.
17
 
Furthermore, they also demonstrated that a subset of MPPs generates preferentially 
megakaryocytes and RBCs showing that the Jacobsen model is more relevant.
17
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Figure 1-1. Proposed models for the hematopoietic hierarchy. 
In the model proposed by the Weissman group (solid arrows), multipotential progenitors 
(MPPs or short-term HSCs [ST-HSCs]) give rise to either a common lymphocyte 
progenitor (CLP) or a common myeloid progenitor (CMP), which, in turn, gives rise to 
either a granulocyte-macrophage progenitor (GMP, equivalent to CFU-GM) or a 
megakaryocyte-erythroid progenitor (MEP). The alternate model suggested by the 
Jacobson group (dotted arrows) involves the generation of MEPs directly from the 
MPPs/ST-HSCs, whereas a lymphoid-primed multipotential progenitor (LMPP) has the 
potential to generate both CLPs and GMPs. LT-HSC, Long-term hematopoietic stem cell; 
NK cell, natural killer cell.  
 
Reprinted with permission: Dzierzak E, Philipsen S. Erythropoiesis: development and 
differentiation. Cold Spring Harb Perspect Med. 2013;3(4).
18
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Table 1-1. Cell surface phenotypes of different hematopoietic populations. 
 
Population Name Surface Markers 
LT-HSC Lin- c-Kit+ Sca1+ Flt3- CD34- 
LT-HSC (SLAM) Lin- c-Kit+ Sca1+ CD150+ CD48- 
LT-HSC (SP) Lin- c-Kit+ Sca1+ Hoechst side population 
ST-HSC / MPP Lin- c-Kit+ Sca1+ Flt3- CD34+ 
LMPP Lin- c-Kit+ Sca1+ Flt3+ CD34+ 
CLP Lin- c-Kit
low
 Sca1
low
 Flt3
high
 IL7Rα+ 
CMP Lin- c-Kit+ Sca1- CD34+ FcγRlow 
GMP Lin- c-Kit+ Sca1- CD34+ FcγR+ 
MEP Lin- c-Kit+ Sca1- CD34- FcγR- 
B-cells B220 
T-cells CD3, CD4 and CD8 
NK cells NK1.1 
RBC Ter119 
Platelets CD41 
Granulocytes Gr-1 
Macrophages Mac-1 
 
HSC: Hematopoietic Stem Cell, LT-HSC: Long Term HSC, ST-HSC: Short Term HSC, 
MPP: Multipotent Progenitors, LMPP: Lymphoid primed multipotent progenitor, CLP: 
Common Lymphoid progenitor, CMP: Common myeloid progenitor, GMP: Granulocyte-
macrophage progenitor, MEP: Megakaryocyte-Erythroid progenitor, Lin: Lineage 
markers. 
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Origins of the Hematopoietic System 
 
Even though the BM is the primary site of hematopoiesis in the adult, the HSCs 
are not normally generated de-novo in the BM but are colonized during embryonic 
development from other sites. During embryogenesis, hematopoiesis occurs sequentially 
at different sites and hematopoietic cells later colonize secondary territories to finally end 
up in the BM (Figure 1-2).
19
 The first wave of hematopoiesis is detectable at embryonic 
day 7.5 (E 7.5) in the yolk sac blood islands. This is called the primitive hematopoiesis 
and it generates red blood cells that express embryonic globins. The primitive 
hematopoiesis is transient and is replaced by definitive hematopoiesis which is 
characterized by expression of adult type globins. The first site of definitive 
hematopoiesis is located in the Aorto-Gonado-Mesonephros (AGM) region at E10.5. In 
this region, “hemogenic endothelial cells” on the ventral side of the dorsal aorta bud off 
hematopoietic stem cells. The hematopoietic cells in the AGM region are capable of 
reconstituting hematopoiesis in lethally irradiated mice.
20
 At a similar time hematopoietic 
clusters are also found in the umbilical arteries, allantois and the placenta.
21-23
 The 
relative contribution of these sites to the final pool of adult HSCs is still unknown. The 
definitive hematopoietic cells then migrate into the fetal liver, thymus, spleen and finally 
the BM (Figure 1-2). The properties of HSCs in these niches are different, for example 
the fetal liver HSCs are cycling compared to the BM HSCs which are mostly quiescent.
19
 
 
 
Transcription Factors in Hematopoiesis 
 
The importance of Transcription Factors (TFs) in hematopoiesis can be 
appreciated by the fact that their dysregulated expression and mutations are frequently 
found in leukemia.
24-26
 Hematopoietic transcription factors can be arbitrarily classified 
into “HSC specific” TFs and “lineage specific” TFs. The HSC specific TFs like Scl/Tal1 
and Runx-1 are required for generation of the HSC. Scl/Tal1 knockout mice is embryonic 
lethal with no blood formation in the yolk sac and embryo indicating its importance in 
both primitive and definitive hematopoiesis.
27-29
 Runx-1 knockout mice had normal 
primitive hematopoiesis but fail to form hematopoietic clusters in the AGM region, the 
first site of definitive hematopoiesis.
30-32
 On the other hand, Lineage specific TFs like 
CEBPα and GATA1are required for the generation of specific lineages. Mature 
neutrophils and eosinophils are absent in the blood and fetal liver of CEBPα-/- mice while 
other lineages are not affected.
33
 Similarly GATA1
-/-
 ES cells do not contribute to mature 
red blood cells in chimeras but do generate other non-erythroid lineages.
34
 
 
However this classification is not strict and frequently HSC specific TFs also have 
other functions in specific lineages and the lineage specific TFs have also have functions 
in the HSCs. Conditional inactivation of SCL/Tal1 in the adult bone marrow did not 
affect HSC self-renewal or maintenance but specifically blocked the differentiation of 
erythroid and megakaryocyte lineages.
35
 Similarly conditional inactivation of Runx1 in 
the adult bone marrow specifically blocked differentiation of megakaryocytes and 
lymphocytes without affecting HSCs.
36
 Conditional inactivation of the lineage specific 
TF, CEBPα in the fetal liver also expanded the HSCs as shown by increased competitive  
 5 
 
 
 
Figure 1-2. Timeline of hematopoietic events in the mouse conceptus. 
Arrows above indicate the onset of specific hematopoietic cell generation and/or 
appearance; arrows below indicate the earliest time of colonization of the secondary 
hematopoietic territories. AGM, Aorto Gonado Mesonephros region. 
 
Reprinted with permission: Dzierzak E, Speck NA. Of lineage and legacy: the 
development of mammalian hematopoietic stem cells. Nat Immunol. 2008;9(2):129-
136.
37
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repopulation.
38
 This shows that lineage specific TFs may also have HSC functions. 
Redeployment of the same TF during different stages of development and differentiation 
is commonly found in hematopoiesis. 
 
Lineage specific TFs promote their own lineage differentiation and at the same 
time antagonize TFs that favor other lineage choices. GATA1 and PU.1 are essential for 
erythroid and myeloid differentiation respectively. N-terminus region of PU.1 was shown 
to physically interact with the C-terminus zinc finger region of GATA1 and prevent its 
function by affecting the DNA binding ability.
39,40
 The C-terminus zinc finger of GATA1 
can also block PU.1 mediated transactivation of myeloid specific genes by interacting 
with its ETS domain.
41
. Forced expression of GATA1 in myeloid cells reprograms them 
to undergo erythroid differentiation.
42
 Forced expression of PU.1 represses erythropoiesis 
and promotes myeloid differentiation in erythroid cell lines.
43
 Morpholino based 
knockdown of PU.1 and GATA1 in zebrafish shifts hematopoietic progenitors into 
erythroid and myeloid fates respectively.
44,45
 TFs can also antagonize each other at the 
level of transcription. For example during erythroid differentiation GATA1 and GATA2 
antagonize each other at the transcriptional level. This phenomenon is called the “GATA 
switch “and will be discussed in detail later. 
 
TFs can also mediate lineage choices in a dose dependent manner. This has been 
demonstrated for PU.1 and GATA1. When PU.1
-/-
 fetal liver cells were transduced with a 
PU.1iresGFP vector and cultured on OP9 cells they differentiate into macrophages and B 
cells. Expression of high GFP in the macrophages and low GFP in the B cells showed 
that PU.1 can differentiate fetal liver progenitors into different lineages based on 
dosage.
46
 Expression of GATA1 in myb-ets transformed avian myeloblasts showed a 
clear co-relation of GATA1 dosage and lineage choice.
47
 Eosinophils formed at low 
doses of GATA1 and erythroid, megakaryocyte development is seen at high doses. 
 
TFs can group together with other TFs and non-DNA binding proteins to form 
multiprotein complexes. In erythroid cells a complex containing Scl/Tal1, E47, LMO2, 
Ldb1 and GATA1 has been reported.
48
 This complex binds to DNA sequences with 
composite elements containing both GATA motif (WGATAR) and E-box motif 
(CAANNTG).
48
 GATA1 also forms an alternate protein complex with its co-factor 
Friend of GATA (FOG). Using GATA1 mutants which cannot bind to FOG1 but have 
normal DNA binding activity, it has been shown that this GATA-FOG complex is 
essential for erythroid and megakaryocyte development.
49
 GATA1-FOG1 complex is 
further associated with the NuRD chromatin remodeling complex in both erythroid and 
megakaryocyte lineages through N-terminus NuRD interaction domain of FOG1.
50
 This 
association can mediate transcriptional repression and also facilitate accessibility of the 
complex to its target regions. 
 
 
GATA Family of Transcription Factors 
 
The GATA binding proteins are a group of structurally related zinc finger 
transcription factors which bind to the consensus DNA sequence WGATAR (W=A/T, 
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R=A/G). In mammals the GATA family contains 6 members (GATA1- GATA6). 
GATA1, GATA2 and GATA3 are primarily expressed in the hematopoietic system. 
GATA1 and GATA3 are lineage specific transcription factors. GATA1 is expressed in 
the erythroid, megakaryocyte and eosinophil lineages whereas GATA3 is expressed in 
the T cell lineage.
51
 GATA2 is broadly expressed in the HSCs, progenitors and mast 
cells.
52,53
 These hematopoietic GATA members are also expressed in other tissues in the 
body. GATA1 is expressed in the Sertoli cells in testes.
54
 GATA2 is expressed in 
endothelial cells, fetal liver, fetal heart, placenta, brain and pituitary glands.
55-59
 GATA3 
is expressed in kidney, central nervous system, placenta, skin and mammary glands.
60-62
 
The other GATA family members, GATA4, GATA5, and GATA6 are expressed in 
tissues of mesodermal and endodermal origins such as heart, liver, lung, gut and 
gonads.
63
 
 
The functions of the hematopoietic GATA factors have been studied using 
knockout mice. GATA1
-/-
 embryos die between embryonic day 10.5 and 11.5 due to a 
block in the differentiation of embryonic erythroid cells. GATA1
-/-
 ES cells in chimeras 
did not contribute to the erythroid lineage but had normal contribution to other lineages.
34
 
Subsequently it was shown that targeted deletion of two control elements in the GATA1 
locus lead to loss of eosinophil lineage and defects in platelet development.
64,65
 These 
experiments showed that GATA1 is required for lineage specification of erythroid, 
megakaryocyte and eosinophil lineages. GATA2
-/-
 embryos die between embryonic day 
10 and 11 due to severe anemia. GATA2
-/-
 ES cells did not contribute to any 
hematopoietic cells showing a defect in HSC formation.
66
 GATA3
-/-
 embryos die due to 
internal bleeding, aberrations in fetal hematopoiesis, abnormalities in spinal cord and 
brain.
67
 GATA3
-/-
 ES cells in RAG2
-/-
 chimeras did not contribute to the T-cell lineage 
but had normal contribution to other lineages.
68
 
 
In some instances the functions of GATA factors were shown to be partially 
interchangeable. When GATA3 is knocked into the endogenous GATA1 locus, the 
mutant mice showed a partial rescue of the GATA1 null phenotype characterized by 
increased survival of erythroid precursors and improved hemoglobin production.
69
 
Transgenic expression of GATA2 and GATA3 could rescue embryonic lethality of 
GATA1 knockdown embryos.
70
 However the adult mice rescued with the transgenes 
developed anemia.
70
 In T-cells GATA3 target genes can be activated and repressed by 
expression of GATA1, 2 and 4.
71
 
 
The GATA factors contain two highly conserved Cys4 zinc fingers. The C-
terminal zinc finger is necessary and sufficient for GATA to bind to cognate sequence 
WGATAR.
72,73
 The N-terminal zinc finger can also bind to DNA sequence containing 
GATC
74,75
 and also mediates binding to co-regulator FOG1. Recently Chip-Seq 
experiments with GATA1,GATA2 and GATA3 factors has shown that GATA factors 
mostly bind to single GATA site ((A/T) GATAA) or a palindromic site 
(catctGATAAG).
76-78
 Crystal structure analysis of DNA binding domain of GATA3 
revealed that the two zinc fingers can wrap around a single GATA site or bridge between 
two sites on different DNA molecules.
79
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GATA2 Gene Structure and Cis-Regulatory Elements 
 
The mouse GATA2 is located on chromosome 6 spanning 8.5kb and can produce 
two mRNA transcripts. The two transcripts differ in their 1
st
 exon which contains part of 
the 5’UTR (Figure 1-3A). The distal 1S exon is utilized in the hematopoietic and neural 
tissues whereas the proximal 1G exon is utilized in all other tissues where GATA2 is 
expressed.
55,80
 The remaining 5 exons are shared by both transcripts. Both the mRNA 
transcripts finally result in production of the same 480 amino acid protein. 
 
Cis-regulatory elements that control GATA2 expression in various tissues were 
mapped using YAC and BAC clones containing GATA2 genomic sequences. The 
d16YAC clone containing -198kb to +73kb region completely rescued the GATA2
-/-
 
hematopoietic defect whereas the d27YAC clone containing -148kb to +73kb region did 
not.
81
 This localized the hematopoietic regulatory elements between -198kb to – 148kb 
region (Figure 1-3B). Even though the d16YAC rescued the hematopoietic defect these 
transgenic pups die at P0 due to urogenital patterning defects.
81
 Two urogenital enhancers 
were then mapped to +75kb (UG4) and +113kb (UG2) region using reporter gene 
expression from BACs.
82
 Two intronic enhancer elements have been identified so far 
(Figure 1-3A). A 190bp region in the intron 5 is required for GATA2 expression in the 
V2 interneurons in the spinal cord.
83
 A 480bp region in the intron 4 drives GATA2 
expression in the HSCs, vascular and lymphatic endothelial cells.
84,85
 
 
Additional cis-regulatory elements called “GATA switch sites” were identified 
using Chromatin immunoprecipitation studies in G1E cell line (Figure 1-3B). GATA1 
binds to 5 dispersed regions in the GATA2 locus (-77kb, -3.9kb, -2.8kb,-1.8kb and 
+9.5kb relative to the 1S promoter) and repress GATA2 transcription.
86-88
 The same 
regions were previously bound by GATA2 when it is actively expressed suggesting a 
positive feedback loop. Targeted deletion of the -1.8kb region reactivates GATA2 
transcription in late stage erythroblasts where it is normally repressed resulting in an 
erythroid maturation defect.
89
 Targeted deletion of the -2.8kb region reduced GATA2 
expression in LT-HSCs and MPPs of fetal liver without affecting their numbers.
90
 
 
 
GATA2 Functions during HSC Specification 
 
GATA2 functions have been studied using conventional knockout, conditional 
knockout and overexpression approaches. Tsai et al. generated the first GATA2 
conventional knockout mice by replacing the exon5 which encodes the 2nd zinc finger 
with the neo cassette.
66
 The GATA2 knockout mice die at E10.5 due to severe anemia. 
Yolk sac of these mice had fewer hematopoietic cells (3 fold reduction), and made lesser 
CFU-C colonies.
53,66
 However the erythroid differentiation was normal. These data 
demonstrate that primitive hematopoiesis is defective upon GATA2 removal. Defects in 
the definitive hematopoiesis were much more profound. Since the mice die at E10.5 
definitive hematopoiesis was studied in chimeras generated by injecting GATA2
-/-
 ES 
cells into wild-type blastocysts. GATA2
-/-
 ES cells did not contribute to any aspects of 
definitive hematopoiesis (fetal liver, adult BM, thymus, spleen and peripheral blood).  
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Figure 1-3. GATA2 gene structure and cis-regulatory elements. 
(A) The GATA2 locus has 6 exons. The 5’ and 3’ untranslated region (UTR) is shown in 
black. Arrows indicate the transcription start sites from the 1S and 1G exons. The 
location of the two intronic enhancers is shown in blue. V2: V2 interneuron enhancer, 
VE: vascular and lymphatic endothelial cell enhancer. (B) Diagram of the entire GATA2 
locus on chromosome 6 showing location the of different enhancer elements. Position of 
the d16 and d27 YAC constructs is shown in reference to the GATA2 locus. The 2 
urogenital enhancers UG4 and UG2 are shown in blue. Locations of GATA switch sites 
are indicated by downward arrows.  
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These data suggested that GATA2 is required for the generation of HSC/progenitor cells. 
 
The GATA2
+/-
 mice are viable with normal blood counts.
91
 However the number 
of HSCs in the AGM region and adult BM generated is lower than wild type mice. In the 
AGM region of the GATA2
+/-
 mice there are lesser Sca1+ cells and lesser reconstitution 
when transplanted into sub lethally irradiated recipients.
92
 In the adult BM there are fewer 
CD34- LSK cells and a competitive repopulation defect into lethally irradiated recipients 
has been reported.
91
 Thus the generation of definitive HSCs is also affected in a dose 
dependent manner by GATA2. 
 
More recently it has been shown using a conditional knockout approach that 
GATA2 is also essential for the generation of the fetal liver HSCs and maintenance of the 
adult HSCs. Cre mediated GATA2 excision at E9-E11 reduced the number of phenotypic 
and functional HSCs in the E14.5 fetal livers in a dose dependent manner.
85
 GATA2 
inactivation in the adult BM also reduced the number of phenotypic HSCs.
85
 Effects on 
the functional HSCs and progenitor compartments could not be addressed because of the 
VE-cre which was not expressed in progenitors. When the embryonic lethality at E10.5 
was surpassed in the conditional knockout, a lymphatic patterning defect was also 
identified.
85
 
 
 
GATA2 Functions during Differentiation and Self-Renewal 
 
After HSCs are specified it appears that GATA2 downregulation is required for 
differentiation and self-renewal. Expression of GATA2 mRNA is highest in HSCs 
followed by progenitor cells and completely absent in mature cells.
52,93,94
 Enforced 
expression of GATA2 using a retroviral vector in wild type murine BM resulted in a loss 
of hematopoietic progenitor derived colony formation.
95
 GATA2 expressing Lin- Sca1+ 
cells (HSCs) did not expand in the BM of transplant recipients and these primitive cells 
did not contribute to long term multilineage reconstitution.
95
 Even the cells expressing 
GATA2 during short term reconstitution had progressively decreasing levels of GATA2 
over time.
95
 Similar effect was also seen upon enforced expression of GATA2 in human 
cord blood cells transplanted into NSG mice.
96
  
 
GATA2 downregulation can be mediated by the antagonistic action of other 
lineage specific transcription factors. This has been demonstrated in erythroid and 
myeloid lineages where the lineage specific transcription factors GATA1 and PU.1 
downregulates GATA2. G1E cell line is derived from in vitro differentiation and 
immortalization of GATA1
-/-
 ES cells.
97
 G1E cells are arrested in the pro-erythroblast 
stage due to loss of GATA1 and they express high levels of GATA2.
49,98
 Upon 
restoration of GATA1, GATA2 is downregulated and these cells can differentiate into 
mature erythroid cells.
97,98
 GATA1 downregulates GATA2 expression by displacing 
GATA2 at 5 regions in the GATA2 locus itself (-77kb,-3.9kb, -2.8kb,-1.8kb, +9.5kb) and 
disrupting its positive feedback loop.
98
 Similarly PU.1
-/-
 hematopoietic progenitors from 
fetal liver can be cultured in vitro and upon restoration of PU.1 can differentiate into 
macrophages by down regulating GATA2.
99
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GATA2 also downregulates the lineage specific transcription factors in progenitor 
cells. This has been observed in G1ME cells which is another cell line derived from 
GATA1
-/-
 ES cells. The G1ME cells are arrested in the MEP stage due to absence of 
GATA1. Interestingly in the G1ME cells GATA2 binds to the PU.1 locus preventing its 
expression.
100
 Accordingly, knockdown of GATA2 in G1ME cells resulted in up-
regulation of PU.1 and macrophage differentiation. 
 
The only mature lineage which requires constant GATA2 expression is the mast 
cells. Requirement of GATA2 in this lineage was identified when GATA2
-/-
 yolk sac 
cells could not be differentiated in vitro into mast cells in the presence of SCF.
53
 GATA2 
is also highly expressed in proliferating mast cells.
101
 GATA2 expression can 
differentiate PU.1 rescued hematopoietic progenitors into mast cells.
99
 GATA2 can also 
instruct GMP cells into mast cells when CEBPa is suppressed.
102
 GATA2 has also been 
shown to instruct eosinophil and basophil differentiation from GMPs upon sequential 
expression with CEBPa.
102
 However it is not clear whether GATA2 is required in these 
lineages since GATA1 is also expressed in eosinophils and basophils and GATA1 is 
required for the generation of the eosinophil lineage. GATA2 overexpression has also 
been reported to expand megakaryocytes and also implicated in Down’s Syndrome 
AMKL associated with a GATA1short isoform.
103-105
 
 
 
GATA2 Effects on Cell Cycle 
 
GATA2 has also been shown to mediate cellular quiescence. GATA2 expression 
is higher in the quiescent HSCs than the cycling HSCs.
96
 It is possible that the 
downregulation of GATA2 brings the HSCs into cell cycle during differentiation and 
self-renewal. In myeloid cell lines (32D, BaF3 and FDCP Mix), enforced expression of 
GATA2 using a conditional GATA2-ERT system mediates quiescence. The mechanism 
proposed was GATA2 down-regulates c-myc, resulting in decrease in Cul1 and Skp2 (E3 
ubiquitin ligase complex) and accumulation of p21/p27 cell cycle inhibitors.
106
 It was 
also shown in BaF3 cells that this quiescent state is reversible upon removal of the ligand 
tamoxifen. 
 
 
GATA2 Chromatin Occupancy  
 
Two studies have reported the GATA2 chromatin occupancy in HSCs and 
Progenitor cells (HSPCs) .Wilson et al. did chromatin immnoprecipitation followed by 
deep sequencing (CHIP-SEQ) of GATA2 and 9 other transcription factors in a murine 
hematopoietic progenitor cell line HPC-7.
107
 In this study GATA2 binding regions 
significantly overlapped with that of other transcription factors SCL, LYL1, LMO2, and 
RUNX1. In addition these five transcription factors were found frequently at ERG and 
FLI-1 binding sites. Together these 7 transcription factors form the “HSC heptad” and 
their targets were enriched for genes expressed in HSCs. Li et al. did CHIP-SEQ of 
GATA2, SCL and Ldb1 in primary lineage negative murine bone marrow cells.
108
 Ldb1, 
an adapter protein was bound to all the genes which were occupied by GATA2 and SCL. 
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This suggests that Ldb1 is an important part of the complex containing GATA2 in 
HSPCs. 
 
GATA2 binding sites during differentiation of erythroid cells and megakaryocytes 
have been studied extensively using Chip assays on G1E and G1ME cell lines. Both the 
cell lines are derived from in vitro differentiation of GATA1 null ES cells.
97,109
 G1E cells 
are arrested in the pro-erythroblast stage and G1ME cells are arrested in Megakaryocyte 
Erythroid Progenitor stage. Upon GATA1 rescue both G1E and G1ME cells differentiate 
into mature erythroid and megakaryocytes respectively. Both G1E and G1ME cells 
initially have high expression of GATA2 and downregulate it as they differentiate due to 
GATA1 rescue. Chromatin immunoprecipitation studies during this process have 
revealed that GATA1 displaces GATA2 from binding sites in target genes. This 
phenomenon is called as “GATA switch” leads to altered transcription of the target 
genes.
110
 GATA switch sites were identified in genes like β-globin, GATA2, c-kit111, 
Lyl1
112
, PU.1
100
 and mir144/451 microRNA cluster.
113
 Few examples are show below. 
 
In the β-globin locus of G1E cells, the initial GATA2 binding results in low level 
globin expression.
114
 Upon GATA1 rescue, GATA1 displaces GATA2 resulting in high 
level globin expression during erythroid differentiation. In the c-kit and GATA2 loci, the 
initial GATA2 binding results in active transcription of these progenitor genes. GATA2 
is shown to co-occupy with SCL in these loci. During the GATA switch GATA1 replaces 
GATA2 and the SCL occupancy is lost resulting in transcriptional repression. In the PU.1 
locus, GATA2 is co-occupied with FOG-1 resulting in transcriptional repression of a 
myeloid gene. During GATA switch, GATA1 replaces GATA2 interacting with FOG-1 
and resulting in further repression and reinforcing erythroid differentiation. Other 
myeloid transcription factors like MpO, CEBPα and Hhex were also bound by GATA2 
and repressed in G1ME cells.
104
 Knockdown of GATA2 in G1ME cells results in 
myeloid trans-differentiation underscoring the importance of this GATA2 mediated 
repression of myeloid genes in the MEP.
100
 GATA2 also binds to and upregulates mast 
cell genes in G1E cells which is shut off after GATA switch.
115
 
 
ChIP-Seq analysis of K562 cell line have identified GATA2 binding to the locus 
of co-repressor ETO-2.
76
 In G1E cells GATA2 binding and activation of ETO-2 was 
confirmed. Interestingly upon GATA1 rescue, ETO-2 binds and represses its own locus 
facilitating GATA1 mediated differentiation. ChIP-Seq analysis on G1ME cells identified 
co-occupancy of GATA2 and ETS-1 transcription factor.
116
 This study also pointed out 
that GATA2 binding sites were enriched in the regions within genes and especially in 
the1st intron.
116
 
 
ChIP-PCR analysis of several GATA sites in G1E cells showed that GATA2 
binds only to a small proportion of WGATAR motif in complex with an E-Box motif 
(SCL binding site).
117
 High percentage of GATA2 bound sites were also bound by SCL 
and have a specific epigenetic signature. The GATA2 bound sites were associated with 
acetylated histones H3 and H4 that were dimethylated at H3K4 and H3K36, and devoid 
of H3K9 trimethylation.
117
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GATA2 Mutations in Acute Myeloid Leukemia 
 
GATA2 mutations were reported in several syndromes associated with 
predisposition to AML and MDS (Table 1-2). Hahn et al reported two GATA2 missense 
mutations (T354M and T355del) associated with familial MDS and AML.
118
 These 
mutations were heterozygous in the affected individuals and there was incomplete 
penetrance among family members. The T354M mutant showed dominant negative 
effects and the T355del mutant show loss of function in in vitro experiments (reporter 
assays, cell lines). The T354M mutation was also reported in two other syndromes with 
similar clinical features called the MonoMAC syndrome and the DCML syndrome. Both 
the syndromes were characterized by monocytopenias, B-cell and NK cell deficiency, 
mycobacterial and HPV infections with predisposition to MDS and AML. There were 
several other overlapping mutations between these two syndromes (Table 1-2). Most of 
the missense mutations are located in the 2
nd
 zinc finger of GATA2. Others include N-
terminal frame-shift mutations resulting in pre-mature stop codons and complete 
deletions of the 2
nd
 zinc finger. Using exome sequencing Ostergaard et al identified 
GATA2 mutations in a disease of primary lymphedema associated with MDS /AML 
called the Emberger syndrome.
119
 The mutations did not overlap with previous diseases 
which show that the lymphatic defects require a different set of mutations. Activating 
mutations of GATA2 were also found in CML blast crisis phase. Recently sequencing of 
the genome of pediatric non-Down’s syndrome Acute Megakaryocytic leukemia 
(AMKL) patients identified GATA2-HoxA9 fusion. In this fusion GATA2 N-terminus 
lacking the zinc-fingers was fused to the homeodomain of the transcription factor 
HoxA9. So far none of the GATA mutations have been reintroduced into mice to test if 
they cause the disease.  
 14 
Table 1-2. GATA2 mutations in myeloid neoplasms. 
 
Syndromes Amino Acid 
Changes 
Clinical Features References 
Familial MDS/AML T354M Predisposition to MDS 
and AML 
Hahn et al.
118
 
 T355del 
    
MonoMAC 
syndrome 
R398W Monocytoopenia 
B and NK cell 
deficiency 
Mycobacterial and 
Papilloma virus 
infection 
Predisposition to MDS 
and AML 
Hsu et al.
120
 
 T354M 
 G81fs 
 N371K 
 R361delRNAN 
 M1del290 
 R396W 
 R396Q 
 D259fs 
 N317fs 
 P254L 
 Δ340-381 
    
DCML syndrome G200fs Same as MonoMAC 
syndrome 
Dickinson et al.
121
 
 T354M 
 R398W 
 Δ340-381 
    
Emberger syndrome L105Pfs Primary lymphedema 
Cutaneous warts 
Deafness 
Predisposition to MDS 
and AML 
Ostergaard et al.
119
 
 R78Pfs 
 R337X 
 A341Pfs 
 C373R 
 R361L 
 A194Sfs 
    
CML blast crisis L359V Blast crisis in CML Zhang et al.
122
 
 Δ341-346 
    
Pediatric AMKL GATA2-HoxA9 
fusion 
Non Down’s 
syndrome AMKL 
Gruber et al.
123
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CHAPTER 2.    MATERIALS AND METHODS 
 
 
Vector Construction  
 
 
Construction of the inducible GATA2-ERT vectors 
 
MSCV-GATA2iresGFP and MSCV-iresGFP gamma-retroviral constructs have 
been described previously.
95
 To generate the MSCV-GATA2-ERTiresGFP vector, the 
human GATA2 cDNA was cloned into the MSCV-ERTiresGFP vector, which contains 
the ligand binding domain of the ERT estrogen receptor variant (G521R) which is 
responsive only to Tamoxifen.
124
 The GATA2 fragment was released from the 
MSCV-GATA2iresGFP vector (NcoI digest) and ligated upstream of mutant ERT (EcoRI 
digest) after Klenow fill-in. This cloning strategy removed the stop codon and the last 
aminoacid (G) from GATA2 cDNA and generated a 7 aminoacid linker (NSDPRNE) 
between GATA2 and ERT. The GATA2-ERTiresGFP fragment was then moved from 
the gamma retroviral to the lentiviral pCL10.1 GFP vector using EcoRV and NotI sites to 
generate the pCL10.1-MSCV GATA2-ERTiresGFP vector.
125
 The lentiviral vector was 
only used to generate the GATA2-ERT transgenic mice. All other experiments were 
performed with the gamma retroviral vector. 
 
 
Construction of the GATA2 DNA binding mutants 
 
The wild type human GATA2 cDNA was first transferred to pUC19 Shuttle 
vector for subsequent site-directed mutagenesis. MSCV GATA2-ERT retroviral construct 
was cut with EcoRI to release the hGATA2 cDNA fragment (1.4 kb). The pUC19 vector 
was linearized with EcoRI and ligated to the above hGATA2 fragment to generate the 
pUC19 GATA2 vector .The mutagenic primers were designed using the QuickChange 
primer Design application from Agilent Technologies. Wildtype reverse primers were 
designed to run in the opposite direction starting from the mutagenic primer. The 
following primers with 5 ' phosphorylation were utilized: C352P (Forward, 
5’- AGCCGGCACCTGTTGTGCAAATCCTCAGACGACAAC-3’; Reverse, 
5’- CTTCTGGCGGCCGACAGTCTTCGC-3’), C370P (Forward, 
5’- CGGGGACCCTGTCCCCAACGCCTGTGGC-3'; Reverse, 
5’- TTGGCGTTTCGGCGCCATAAGGTG-3'). 
 
The pUC19 GATA2 plasmid was linear amplified with the desired mutations 
using the Phusion Hot Start II DNA Polymerase (Thermo Scientific). Then the plasmid is 
then circularized by ligation and transformed into NEB Turbo Competent E.Coli .The 
pUC19- GATA2 mutants were sequence verified using the following sequencing primers: 
5’- GGCTCGTTCCTGTTCAGAAG-3', 5'-CTTCTCCAAGACGCCACTGC-3'). The 
mutant Zinc finger domains were then switched between the retroviral vectors MSCV-
GATA2-ERTiresGFP and MSCV-GATA2iresGFP from the pUC19-GATA2 vectors 
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using SacII and BamHI sequential digests .The mutant retroviral vectors were sequence 
verified again using the above primers before vector production. 
 
The pCDNA3.1 constructs containing the wild type and mutant GATA2 and 
GATA2-ERT cDNA were generated for in vitro transcription and translation for the 
EMSA assays. The pCDNA3.1-GATA2 constructs were generated by cloning of the 
GATA2 fragment from the retroviral vectors using EcoRI and EcoRV enzymes .Then the 
pCDNA3.1-GATA2-ERT constructs were generated by replacing the GATA2 
C-terminus region of the pcDNA3.1-GATA2 vector with the GATA2 C-terminus ER 
from each of the retroviral GATA2-ERT vectors .SacII and EcoRV was used for the 
pcDNA3.1-GATA2 vector. SacII and ClaI (blunt) was used for the inserts from the 
MSCV-GATA2-ERT vectors. 
 
 
Construction of a lentiviral mir30 based shRNA vector 
 
LMP-RFP vector (MSCV-mir30PGK-puroiresRFP), a retroviral mir30 based 
shRNA vector was a kind gift from the Dr. Richard Gilberson's lab. The LMP-RFP 
vector is a derivative of the LMP vector from Gregory Hannon’s Lab.126 The “PGK puro 
ires” fragment was replaced with the "PGK" fragment from the pCL-c-MNDU3 PGK 
GFP vector using the BlpI and NcoI restriction sites. The RFP reporter was replaced with 
PCR amplified m-cherry cDNA .The m-cherry cDNA was PCR amplified from the 
pCL20-MSCV-CreERT2-Ires-mCherry vector using the following primers: m-cherry 
Forward,5’- GTGAGCAAGGGCGAGGAGGATA-3’; m-cherry Reverse (ClaI) 
5’-TTTTTTATCGATGCTACTTGTACAGCTCGTCCA-3’.The entire mir30 cassette 
with m-cherry reporter was then moved to the lentiviral backbone of pCL20cGFP vector 
using ClaI and EagI sites.
127
 Finally an XhoI site outside the viral LTR was removed to 
generate the pCL20c-mir30mcherry vector .This vector was used for direct single step 
cloning of the hairpins in the future. 
 
 
Cloning of the hairpins targeting genes of interest into the pCL20c mir30 m-cherry 
vector 
 
The 137 bp sequences containing the hairpins were designed using the shRNA 
psm2 Design from the Greg Hannon Lab website 
(http://katahdin.cshl.org/siRNA/RNAi.cgi?type=shRNA). 3-5 oligonucleotides were 
designed for each of the gene targets (Table 2-1) and single strand template PCR was 
performed as described previously.
128
 The PCR products were digested using EcoRI and 
XhoI sites and ligated into the unique XhoI and EcoRI sites in the pCL20c-mir30mcherry 
vector. VSV-G pseudotyped lentiviral vector particles were prepared using a 4-plasmid 
system using transient transfection of 293T cells, as previously described below. 
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Table 2-1. Primers used for mir30 based short hairpin cloning. 
 
Name Sequence 
5'miR30PCRxhoIF 5’-CAGAAGGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCG-3’ 
3'miR30PCREcoRI
F 
5’-CTAAAGTAGCCCCTTGAATTCCGAGGCAGTAGGCA-3’ 
Sequencing primer 5’-CCCTTGAACCTCCTCGTTCGACC-3 
shNmyc 5’-TGCTGTTGACAGTGAGCGACCTGGCGAGCTGATCCTCAAGTAGTGAAGCCACAGATGTACTT
GAGGATCAGCTCGCCAGGCTGCCTACTGCCTCGGA-3’ 
shHoxA9 5’-TGCTGTTGACAGTGAGCGCGGAGTTTCTGTTTAACATGTATAGTGAAGCCACAGATGTATACA
TGTTAAACAGAAACTCCTTGCCTACTGCCTCGGA-3’ 
shGFP 5’-TGCTGTTGACAGTGAGCGAGCACAAGCTGGAGTACAACTATAGTGAAGCCACAGATGTATAG
TTGTACTCCAGCTTGTGCCTGCCTACTGCCTCGGA-3’ 
NS 5’-TGCTGTTGACAGTGAGCGATCTCGCTTGGGCGAGAGTAAGTAGTGAAGCCACAGATGTACTT
ACTCTCGCCCAAGCGAGAGTGCCTACTGCCTCGGA-3’ 
 
The “sense-loop-antisense” regions of the 97bp “mir30-like “DNA oligonucleotides are highlighted in “blue-red-blue” format. The 
5’miR30PCRxhoIF and 3’miR30PCREcoRIF were used to perform single strand template PCR “NS” denotes non-silencing vector.  
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Vector Production and Titration 
 
 
Lentviral vector production 
 
We seeded 293T cells at about 15×10
6
 cells per 10 cm plate in the morning. Six 
hours after plating the cells, lentiviral helper plasmids and the vector plasmids were 
transfected using calcium phosphate method. The amounts of the plasmids used per 
10 cm plate are Vector – 10 µg; GP1-1 – 6 µg; RTR2 – 2 µg and VSVG – 2 µg. Ten 
plates were transfected at a single time. In a 50 ml conical tube, plasmids required for 10 
plates were mixed with 500 µl of calcium phosphate and water to a total volume of 5 ml. 
Then 5 ml of 2× HSBSS solution was added drop by drop while continuously vortexing 
the tube. The tube was then allowed to sit for 10-15 minutes. One ml of the transfectant 
was added to each of the 10 cm plates and mixed by tilting .The plates were incubated 
overnight and media was replaced with DMEM and 10% Fetal Bovine Serum (FBS). 
Twenty four hours after replacing the media the virus supernatant was collected from the 
plates and pooled. The supernatant was filtered through a 0.22 micron filter (Steriflip) to 
remove any cell debris. Aliquots of the filtered virus supernatant were then flash frozen 
in dry ice and stored at -80°C. A small aliquot was taken to titer the virus at this time on 
293T cells. 
 
 
Retroviral vector production - transient prep 
 
We seeded 293T cells at about 8×10
6
 cells per 10cm plate in the morning. Six 
hours after plating the cells, retroviral helper plasmids and the vector plasmids were 
transfected using calcium phosphate method as described above for the lentiviral 
production. The amounts of the plasmids used per 10cm plate are Vector- 10 µg, Old gag 
pol- 5 µg, VSVG- 1 µg. The transfected plates were incubated overnight and media was 
replaced with DMEM and 10% Fetal Bovine Serum (FBS). Forty eight hours after 
replacing the media the virus supernatant was collected from the plates and pooled .The 
supernatant was filtered through a 0.22 micron filter (Steriflip) to remove any cell debris. 
The virus supernatant was stored in ice and used for transduction of GPE-86 producer 
cells in the following days. 
 
 
Generation of GPE-86 producer cells 
 
We seeded 0.5×10
6
 GPE-86 cells in a 10 cm plate. After 6 hours 5 ml of the 
media was removed and replaced with 5 ml of viral supernatant with polybrene. Every 12 
hours the media was replaced with 5 ml of viral supernatant and 5 ml of fresh media. The 
transduction was carried out for 7 days and then evaluated by flow cytometry. Usually 
more than 90% of producer cells were transduced at this time and they were frozen down 
for future retroviral production. 
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Retroviral vector production from GPE-86 producers 
 
The producers were thawed and split at least 3 times before collecting the virus. 
Virus supernatants were collected 48 hours after the media change .The supernatants 
were filtered and frozen down in -80°C. A small aliquot is taken to titer the virus at this 
time on 3T3s. 
 
 
Vector titration 
 
We seeded 293T or 3T3 cells at a concentration of 0.5×10
6
 cells per 10 cm plate. 
Six hours after seeding increasing amounts of the lentiviral or retroviral supernatant was 
added to each of the plates. The plates were transferred to a CO2 incubator. After 4 days 
the cells were lifted using trypsin and percentages of GFP positive cells (GFP %) were 
analyzed using Flow Cytometry. The virus titer represented as Transducing units /ml 
(TU/ml) is calculated using the following formula. 
 
                    
                
                                
  
 
 
Isolation of Bone Marrow Cells and Transduction 
 
 
Mice  
 
The GATA2-ERT transgenic mice were generated by transduction of murine 
blastocysts with lentiviral pCL10.1 MSCV GATA2-ERTiresGFP vector supernatants. 
The GATA2-ERT transgenic mice were routinely identified by measuring the GFP 
marking in lymphoid and myeloid cells of peripheral blood. All the other experiments 
were performed on 8 -12 weeks old female C57Bl/6 mice (Jackson Laboratories, Bar 
Harbor, ME). All experimentation with mice was performed under protocols approved by 
the Institutional Animal Care and Use Committee of St Jude Children’s Research 
Hospital. 
 
 
Isolation and transduction of lineage depleted mouse BM cells 
 
Bone marrow was harvested from 8 to 12 weeks old female C57BL/6J mice (The 
Jackson Laboratory, Bar Harbor, ME). Mice were sacrificed in the CO2 chamber and then 
rinsed with 70% Ethanol. Tibiae and femurs were dissected out removing the muscles 
and skin tissues. The ends of these bones were trimmed using scissors. The bone marrow 
was then flushed with 2% FBS in PBS using a 25 G needle for the femur and 27 G needle 
for the tibia. The bone marrow collected from all the bones was then flushed one more 
time using the 19 G needle and then filtered through 40 µ filter. The cells were then 
counted using methylene blue and 1% acetic acid to exclude the RBCs. The cells were 
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spun down in the centrifuge at 1200 rpm for 10 minutes. After removing the supernatant 
by suction the cell pellet was resuspended in AutoMACS buffer (40 µl per 10
7 
cells). The 
biotin antibody cocktail which contains biotinylated antibodies against mouse CD5, 
CD45R (B220), CD11b (Mac1), Gr-1 (Ly6G/C), 7-4 and Ter-119 was then added (10 µl 
per 10
7
 cells). The cells were mixed well and incubated at 4°C for 10 minutes. This was 
followed by addition of AutoMACS buffer (30 µl per 10
7
 cells) and anti-biotin 
microBeads (20 µl per 10
7
 cells). The beads were mixed well and incubated for an 
additional 15 minutes at 4°C. The cells were washed by adding more AutoMACS buffer 
(2 ml per 10
7
 cells) and centrifuged at 1200 rpm 10 minutes. After removing the 
supernatant by suction the cell pellet was resuspended in AutoMACS buffer (3 ml for 
2X10
8
 cells). The lineage depleted cells were separated using the AutoMACS
TM
 separator 
using the "depletes" setting. The purity of these cells was tested by staining the cells for 
c-kit and anti-biotin antibodies followed by flow cytometry and consistently achieved 95-
99% purity. 
 
The lineage depleted cells were prestimulated for two days in the presence of  
20 ng/ml recombinant mouse IL-3, 50 ng/ml recombinant human IL-6 and 50 ng/ml 
recombinant mouse SCF (PeproTech) and Dulbecco's modified Eagle medium (DMEM) 
supplemented with 15% fetal bovine serum (FBS), 100 units/ml penicillin, 100 µg/ml 
streptomycin, 2 mM L-glutamine (R&D systems, Minneapolis, MN). After 
prestimulation the cells were transferred into plates coated with 25 ug/ml of retronectin 
(Takara, Madison, WI).The viral supernatant was added at multiplicity of infection 
(MOI) between 1.5 - 3 every 12 hours. After four rounds of transduction the cells were 
lifted from the retronectin coated plates by scraping. The cells were directly transplanted 
into lethally irradiated recipients or cultured for an additional 48 hours before performing 
in vitro experiments. 
 
 
Isolation and transduction of 5-FU treated bone marrow cells 
 
We advocated 5-FU intra-peritoneally to mice at a dose of 150 mg/kg. Two days 
after 5-FU administration bone marrow was isolated, filtered and counted as described 
above. The bone marrow cells were plated at a concentration of 2×10
6
 cells/ml with 
DMEM and 15% FBS and cytokines (IL-3 – 20 ng/ml , IL-6 50 ng /ml , SCF 50 ng/ml ) 
for prestimulation. After 24 hours of prestimulation the cells were lifted by scraping and 
counted. We plated 20×10
6
 cells in retronectin coated 15 cm plates with virus supernatant 
and fresh media containing cytokines and protamine sulphate. Every 12 hours the media 
was replaced with fresh viral supernatant. Four transductions were carried out by this 
method. Six hours after the last transduction the cells were lifted by scraping and 
transplanted into lethally irradiated recipient mice. A small fraction of cells were cultured 
for another 48hrs and assessed for bulk transduction by flow cytometry.  
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Transduction of GATA2-ERT and GFP cell lines with the lentiviral shRNA vectors 
 
We transduced 1×10
6
 cells with the viral supernatant at a MOI of 15-20 in 
retronectin coated 6-well plates. The cells were transduced every 24 hours for a total of 
three hits. One day after the last transduction the cells were lifted and re-plated into 
suspension plates. After 48 hours the m-cherry % was determined and the liquid culture 
started. 
 
 
Functional Assays 
 
 
Bone marrow transplantation  
 
Transduced BM cells were harvested and either diluted with untransduced cells or 
kept undiluted in PBS with 2% FBS. Female C57Bl/6 mice between 10 to 12 weeks of 
age were given a total body irradiation of 1125 cGy from a 
137
Cs source (J.L. Shepherd, 
San Fernando, CA, USA). We injected 2.5×10
6
 cells in a volume of 0.5 ml as a single 
dose by tail -vein injection to each recipient. All the transplant recipients received anti-
bacterial prophylaxis (Baytril 2.27% solution Bayer) for three weeks post transplantation. 
Peripheral blood analysis on the recipients was performed at 8, 12, 16 and 20 weeks post-
transplant. 
 
 
Liquid culture  
 
The liquid culture experiments were initiated 48 hours after the last transduction. 
Cells were lifted from the plates and counted. The percentages of the transduced cells 
were determined by flow cytometry. For the in vitro competition experiments the 
transduced cells were diluted with mock cells to start at a uniform GFP percentage of 
20%. For the knockdown experiments no dilution was performed. Cells were plated at a 
starting concentration of 3.3×10
5
 cells/ml. Every 3 days the cells were counted, 
percentages of transduced cells were measured by flow cytometry and replated again at 
3.3×10
5 
cells/ml. The cells were cultured in DMEM with 15% FBS and cytokines 
(murine IL-3 20 ng/ml, human IL-6 50 ng/ml and murine SCF 50 ng/ml). 
 
 
Colony assay 
 
Fifteen ml conical tubes containing three ml aliquots of Methocult GF M3434 
(Stem Cell Technologies) were thawed at room temperature or 37°C water bath. For 
plating primary colonies 0.3 ml cell suspension containing 3.75×10
3
 cells was added to 
the 3ml of M3434 media. The tube was vortexed and allowed to stand for 5 minutes to 
dissipate the bubbles. Total volume of 1.1ml media containing cells was dispensed into 
two 35 mm plates using a 16 gauge blunt needle and 3cc syringe. After 7 days the plates 
were counted in a microscope with 4× objective for total colonies and GFP positive 
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colonies. For subsequent re-plating the colonies were disrupted into single cell 
suspension by adding 2.5 ml of DMEM and flushing through a 19G needle. The cells 
were washed using 30 ml of DMEM and spun down at 1200 rpm for 10 minutes. The 
cells were resupsended in a smaller volume (0.5 -1ml) and counted. The cells were 
replated at 2.5×10
4
 cells / plate and counted for colonies after 7 days. 
 
 
Cell cycle assays 
 
GATA2-ERT cell lines cultured with 100 nM Tamoxifen or Ethanol were stained 
for DNA content using propidium iodide (PI) at the time points indicated. One million 
cells were spun down, washed once with PBS and lysed in one ml hypotonic solution 
containing PI and detergent (0.05 mg/ml propidium iodide, 0.1 % (w/v) sodium citrate, 
0.1 % (v/v) Triton X-100) by vortex. Samples were then treated with DNAse-free RNAse 
(Calbiochem cat # 556746) for 30 minutes at room temperature. Samples were then 
filtered through 40u mesh and analyzed by flow cytometry. We also performed cell cycle 
analysis on the shRNA vector transduced GATA2-ERT cell lines by incubating with 
Hoechst 33342 at 10 µg/ml for 1 hour followed by FACS analysis. ModFit Analysis 
(Verify Software House) was performed on total population (PI method) or select gated 
population (Hoechst method). 
 
 
Flow cytometry and cell sorting 
 
Single-cell suspensions were prepared from thymus and bone marrow (femoral 
and tibial bones) by passage through a 70-micron cell strainer (BD). Cells were 
resuspended in PBS with 2% FCS. About 70 µl of blood was obtained from mice by 
retro-orbital puncture and RBC lysis was performed with BD FACS Lyse Wash 
Assistant. Cells were stained for 30 min with fluorochrome-conjugated or biotin-
conjugated antibodies. Cells were then washed with excess medium and were 
resuspended in PBS with 2% FCS containing a dead cell marker (PI or DAPI) or stained 
again with secondary antibodies. FACSCalibur, LSR and LSRII (BD Biosciences), were 
used for flow cytometry and BD Aria (BD Biosciences) was used for cell sorting. For 
sorting LSK cells, BM from GATA2-ERT transgenic mice was enriched for Sca1 and 
c-kit markers using anti-PE, anti-APC magnetic beads in AutoMACS before staining 
with Lineage-PECy7 antibodies. For sorting individual progenitor and stem cell 
populations BM from C57Bl/6 mice were lineage depleted as described above prior to 
staining with other progenitor and stem cell markers. Antibodies used are shown in Table 
2-2. 
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Table 2-2. Antibodies used for flow cytometry and cell sorting. 
 
Epitope Clone Conjugate Company 
CD3e 145-2C11 APC BD 
CD3c 17-A2 PE BD 
B220 RA3-6B2 eFlour605 , PEcy7 BD 
Mac1 M1/70 APC-Cy7 , Alexa-700 , PE-Cy7 BD 
Gr-1 RB6-8C5 APC, APC-Cy7, PE-Cy7 BD 
CD34 RAM34 PE BD 
FcγR 2.4G2 Alexa-700 BD 
Sca1 E13-161.7 PE, Biotin BD 
c-kit 2B8 APC, APC-Cy7 BD 
CD127 A7R34 APC BD 
Streptavidin  PE Texas Red , PE-Cy7 BD 
CD44 1M7 PE-Cy7 BD 
CD25 PC61 APC BD 
CD4 L3T4 APC-Cy7, PE-Cy7 BD 
CD8a 53-6.7 Alexa700, PE-Cy7 BD 
Ter119 TER119 PE-Cy7 BD 
FcεR1 MAR-1 Biotin Ebioscience 
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Imaging 
 
 
Giemsa staining 
  
We pelleted 5×10
4
 cells in a 1.5 ml tube and resuspended them in 150 µl of PBS 
in 2% FBS. The cytoslide (Thermo Scientific # 59910052) was setup against the 
cytofunnel (Thermo Scientific #1102548) and locked using the cytoclip (Thermo 
Scientific # 59910052). The cell suspension was then loaded into the cytofunnel and spun 
in the Cytocentrifuge at 1000 rpm for 5 minutes (Cytospin 3 - Shandon cytocentrifuge). 
The cytoslide was removed from the cytoclip and stained by dipping into a staining jar 
containing Wright Giemsa Solution (CS434 Fisher) for 1 min. The cyotoslide was then 
washed by dipping in distilled water 3 times 1 min each. The slide was then dried 
overnight and the coverslip was mounted after adding a drop of Cytoseal 60 (Thermo 
scientific). Images were taken using a Nikon microscope in 20× objective or 40 × oil 
objectives respectively. 
 
 
Immunostaining and confocal microscopy 
 
Coverslips (22 X 22-1 Fisherbrand) were placed in 6-well plates and coated with 
retronectin for 2 hours at room temperature. Retronectin coated coverslips were washed 
once with PBS and incubated with cells at 37°C for 40 minutes. After cell attachment the 
coverslips were washed twice with PBS and fixed with 4% paraformaldehyde for 30 
minutes. Coverslips were washed again twice with PBS and permeablized with 0.1% 
Triton X-100 for 15 minutes. Edges of the coverslips were then dabbed in paper and 
blocked with Fx-signal enhancer (Invitrogen) for 30 minutes. All antibodies were 
prepared in 10% normal goat serum in PBS. Coverslips were incubated with primary 
antibody (1:50) overnight at 4°C. Coverslips were washed three times by dipping in 
beakers containing PBS. Secondary antibody (1:50) was incubated 1 hour at RT. After 3 
washes coverslips were incubated with 0.2 µg/ml of DAPI for 10 minutes. After wash 
with water the coverslips were mounted into glass slides (Fisherbrand Superfrost Plus) 
using Prolong Gold with DAPI mounting media (Invitrogen). Slides were cured overnight 
at room temperature. Edges were secured by applying nail polish and visualized in Zeiss 
LSM 510 NLO Meta confocal microscope.  Antibodies used are shown in Table 2-3. 
 
 
Molecular Techniques 
 
 
RNA isolation and real - time PCR 
 
When the starting cell numbers was more than 0.5×10
6
 cells, Ribopure Kit 
(Ambion AM1924) was used to extract RNA. RNAqueous-Micro Kit (Ambion AM1931) 
was used when the starting cell numbers was less than 0.5×10
6
 cells. RNA extraction was 
performed according to the kit protocols. The RNA concentration and purity was   
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Table 2-3. Antibodies used for immunostaining (IHC) and western blot (WB). 
 
Name Dilution Company Catalog 
Number 
αGATA2 1:1000 (WB) , 
1:50 (IHC) 
Santa Cruz sc-9008 
αER alpha 1:1000 (WB) , 
1:100 (IHC) 
Santa Cruz sc-542 
αLamin B   1:200 (WB) Santa Cruz sc-6216 
αGAPDH 1:25000 (WB) Millipore MAB374 
αGFP  1:1000 (WB) Cell Signaling #2555 
Goat anti-rabbit HRP  1:10,000 (WB) Santa Cruz sc-2004 
Goat anti-mouse HRP 1:10,000 (WB) Jackson 
ImmunoResearch 
115-035-062 
Rabbit anti-goat HRP Fc 
Fragment specific   
1:10,000 (WB) Jackson 
ImmunoResearch 
305-036-008 
Goat anti-rabbit Alexa 
Flour 555 
1:100 (IHC) Invitrogen A21429 
Donkey anti-rabbit Texas 
Red 
1:50 (IHC) Jackson 
ImmunoResearch 
711-075-152 
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determined by the NanoDrop 1000 UV-Vis spectrophotometer (Thermo Scientific). The 
cDNA synthesis was performed using the Superscript VILO cDNA synthesis kit 
(Invitrogen). Real time PCR was performed using TaqMan primer probe sets (Table 2-4) 
and TaqMan Fast Universal PCR Master Mix, No AmpErase UNG (Applied 
Biosystems). A cDNA template equivalent of 10ng was used for each reaction. The 
amplification was carried out in the Step One plus Real-Time PCR System (Applied 
Biosystems). 
 
 
Affymetrix array hybridization 
 
RNA purity and concentration was determined by using the NanoDrop 1000 
UV-Vis spectrophotometer (Thermo Scientific). The integrity of RNA was determined by 
electrophoresis analysis using Agilent 2100 BioAnalyzer Lab on a Chip System (Agilent 
Technologies, Santa Clara, CA). The total RNA was processed by the Hartwell Center 
Microarray Core by using the Affymetrix Eukaryote one-cycle target labeling protocol 
(1 µg of total RNA) or the 3' IVT Express (100 ng of total RNA).The RNA was first 
reverse transcribed using oligo dT primers containing T7 promoter followed by second 
strand synthesis. The resulting cDNA was in vitro transcribed with biotnylated 
ribonucleotides to generate the cRNA. The cRNA was hybridized to the 430v2 GeneChip 
array at 45°C overnight. The arrays were then washed and stained with streptavidin -PE. 
The arrays were scanned and an image file was produced. The expression values were 
summarized using the MAS5 algorithm as implemented in the GCOS v1.4 software 
(Affymetrix, Santa Clara, CA). 
 
 
Total protein extraction using Laemelli buffer 
 
One million cells were spun down and washed once with 1ml of PBS. The cell 
pellet was then resuspended in 100 µl of ice cold PBS containing protease inhibitor 
cocktail (Sigma-Aldrich P8340) and AeBSF (Gold Biotechnology) at a 100× dilution. To 
the cell suspension 100 µl of 2× Laemmeli sample buffer (Bio Rad Laboratories) 
containing beta mercaptoethanol (20×) was added and then boiled at 100°C for 5 
minutes. The samples were then stored in -80°C before performing the immunoblot. 
 
 
Table 2-4. TaqMan primer probe sets used for RT-PCR. 
 
Gene Name Catalogue Number 
mouse + human GATA2 Mm00492302_g1 
mouse GATA2 Mm00492300_m1 
mouse mycN Mm00627179_m1 
mouse hoxA9 Mm00439364_m1 
mouse GAPDH Mm9999915_g1   
 
The primer probe sets were purchased from Applied Biosystems. 
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Cell compartment extraction using the Qproteome cell compartment kit 
 
The Qproteome cell compartment kit was purchased from Qiagen (Cat No 
37502). Five million cells were spun down at 500 g for 10min at 4°C and washed twice 
with ice cold PBS. Protease inhibitors and AeBSF (100×) were added to the buffers 
(CE1, CE2 and CE3). The cell pellet was resuspended in 250 µl of buffer CE1 and 
incubated for 10 minutes at 4°C in an end over shaker. After a 1000 g spin for 10 minutes 
the supernatant containing the “cytoplasmic fraction " was extracted. The pellet was 
again resuspended in 250 µl of buffer CE2 and incubated for 30 minutes at 4°C in an end 
over shaker. After a 6000 g spin for 10 minutes the supernatant containing the 
“membrane fraction " was extracted. Seven µl of benzonase was added to the pellet and 
incubated for 15 minutes at room temperature followed by 250 µl of buffer CE3 for 10 
minutes at 4°C in an end over shaker. After a 6800 g spin for 10 minutes the supernatant 
containing the “nuclear fraction " was extracted. All the fractions were then stored in -
80°C before performing the immunoblot. 
 
 
Immunoblot 
 
I added 2× Laemelli buffer containing beta-mercaptoethanol to the protein 
extracts and boiled for 5 minutes at 100° C. The samples were loaded into NUPAGE 
4-12 % Bis-Tris gel (Invitrogen) and run at 200V for 1 hour: 30 min with NUPAGE 
MOPS SDS Running buffer. The gel was then transferred to PVDF membrane using 
NUPAGE transfer buffer at 30V for 1 hour 30 min. The membrane was blocked with 5% 
milk in TBS 0.1% - Tween 20 for 1 hour. The primary antibody was incubated overnight 
at 4°C. After 3 washes with TBS-T the secondary antibody was incubated for 1 hour at 
room temperature. After 3 washes with TBS-T the blot is developed using ECL prime 
western blotting detection reagent (Amersham). Antibodies used and their dilutions are 
shown in Table 2-3. 
 
 
Electrophoretic mobility shift assay 
 
Human wild type and mutant GATA2 and GATA2-ERT proteins were 
synthesized from pCDNA3.1 expression plasmids using the Rabbit reticulocyte TnT kit 
(Promega). Four hundred thousand counts per minute of P
32
 labeled double stranded 
oligonucleotide containing the alpha globin promoter 
(5'-GATCTCCGGCAACTGATAAGGATTCCCTG-3') were incubated with the protein 
lysates in the presence or absence of 500 molar excess of unlabeled double stranded 
oligonucleotides. Binding reactions contained 10 mM Tris, pH 8.0, 40 mM KCl, 0.05% 
NP-40, 6% glycerol, 1 mM DTT, 0.2 g poly dI/dC, 200 µM ZnCl2 and 5 µl of 
synthesized GATA2 and GATA2-ERT lysates. Samples were incubated at 4°C overnight 
and resolved by electrophoresis through a nondenaturing 4% polyacrylamide gel in 0.5 
TBE (45 mM Tris-borate, 1 mM EDTA) at room temperature and analyzed using the 
Storm 860 phosphoimager (Molecular Dynamics, Sunnyvale, California). 
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T4 kinase labeling reaction and annealing reactions 
 
The alpha-globin reverse oligo nucleotides were 5' end labeled using the T4 
Polynucleotide kinase kit (Promega M4101). The labeled oligos were purified using 
Illustra TM ProbeQuant G-50 Micro Columns (GE Healthcare 28-9034-08). The Reverse 
and forward oligonucleotides were annealed in 50mM MgCl2 and 100 mM Tris pH 8.0  
by boiling for 10 minutes followed by slow cooling to Room temperature overnight. 
 
 
TnT reactions 
 
In vitro transcription and translation was performed using the TnT T7 quick 
coupled transcription/translation system (Promega # L1170). Two small scale reactions 
containing 2 µg of the pCNDA3.1 constructs in a 50 µl reaction was setup with either the 
cold methionine or S
35
 labeled methionine. The S
35
 labeled protein lysates was run on a 
4-12 % Bis-Tris gel (Invitrogen) to verify the presence of the GATA2 and GATA2-ERT 
proteins. The unlabeled protein lysates were used in the EMSA assay. 
 
 
Chromatin immunoprecipitation 
 
GATA2-ERT cells were harvested and stained with Gr-1-PE antibody and 
enriched for Gr-1 negative population by FACS sorting. 20×10
6
 cells were crosslinked 
for 10 minutes by adding formaldehyde to a final concentration of 1%. The reaction was 
quenched by adding glycine to a final concentration of 0.125 M for 5 minutes. The fixed 
cells were washed twice with ice cold PBS and the cell pellet was snap frozen in dry ice 
with protease inhibitors and AeBSF. The cell pellet was later thawed and resuspended in 
2 ml of cell lysis buffer (10 mM Tris pH 8.0, 10 mM NaCl, 0.2% NP-40 in water) with 
protease inhibitors and AeBSF for 10 minutes on ice. After a spin of 2500 rpm for 10 
minutes the nuclei pellet is resuspended in 800 µl of Nuclei Lysis Buffer (50 mM Tris pH 
8.0, 10 mM EDTA, 1% SDS in water) and sonicated. The sonication was done with 1.5 
ml microfuge tubes containing 200 µl aliquots in Bioruptor UCD-200 (Diagenode) for 30 
cycles (30s “ON” and 30s “OFF” at 200W). This resulted in a shearing size between 200 
bp to 700 bp. The sheared chromatin was diluted with 5× IP dilution buffer (20 mM Tris 
pH 8.0, 2 mM EDTA, 150 mM NaCl, 1% Triton X-100, 0.01% SDS in water) and spun 
down at 14000 rpm for five minutes to remove any undissolved nuclear material. Two µg 
of a rabbit polyclonal GATA2 antibody (sc-9008, Santa Cruz) or isotype matched 
preimmune IgG (ab37415, Abcam) was added to each 200 µl of chromatin and incubated 
overnight at 4°C in a rotator platform. No antibodies were added to a 200 µl aliquot 
which was used as input control. The chromatin was incubated for an additional 4 hours 
with 20 µl of Protein A Dynabeads (#100.01D Invitrogen). The beads containing 
immune-bound chromatin were collected by placing the microfuge tubes on a magnetic 
stand. The beads were washed three times with wash buffer (1 part nuclei lysis buffer + 4 
parts IP dilution buffer) and then resuspended with 200 µl of elution buffer (100 mM 
NaHCO3, 1% SDS in water). Reverse crosslink was performed at 65°C overnight in the 
presence of Proteinase K. Finally the supernatant containing immunoprecipitated DNA 
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was pooled from several reactions and further purified using QIAquick PCR Purification 
Kit (#28104, Qiagen) according to the kit protocols. Quantitative Real Time PCR is 
performed using SYBR green method with primers indicated on Table 2-5. 
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Table 2-5. Primers used in quantitative chromatin immunoprecipitation assay. 
 
Locus Name Forward Sequence Reverse Sequence 
α-globin promoter  TGACCAAGGTAGGAGGATACTAACTT TTGCCCGGACACACTTCTTAC 
Gata2 (-) 1.8 kb  GCATGGCCCTGGTAATAGCA CAGCCGCACCTTCCCTAA 
Gata2 (-) 2.8 kb  GCCCTGTACAACCCCATTCTC TTGTTCCCGGCGAAGATAAT 
Gata2 (-) 3.9 kb  GAGATGAGCTAATCCCGCTGTA AAGGCTGTATTTTTCCAGGCC 
Gata2 1G promoter AGATACCCAGAAGGTGCACGTC GCAGACCCTGCACCCCT 
Gata2 1S promoter  CCCCTCGAAGTGATGTCGAA TCTGGCTGTCTCTCGGTTCC 
necdin  GGTCCTGCTCTGATCCGAAG GGGTCGCTCAGGTCCTTACTT 
   
mycN -2.2kb ACACCTGTGCTCTTCACT AGGTCCAAGGAAGATAAACGA 
mycN -9.8kb CACCCTGGCCCTTAGAAG AGAGCAGAGAAGAAAGGGAAAG 
mycN +.6kb  GCAGCCGTGACCTACATT CGCGGGGAAAGAAGGAAAA 
mycN +2.3kb GTGTTTCCAGCCTCTTCTGT TGCTGCGTTCCCTTTGTT 
mycN +3kb  CACAGCCCCATGGAAAAAAA CTACCACTGCCGCTCCTAA 
mycN +3.2 kb AAGTGCAGGCTTATCACCAA CCAGCCCCCCTATTAGAC 
mycN 6.5kb GCGTGTCTGGCATTTGAG CCCTGCCCAGATGATTCT 
   
HoxA9 -3.8kb GTGGTGGACAGGATAAAATGGA GCTGTGCGTGGAAAAAGA 
HoxA9 -1.2kb AATGGCAGAGAAGAGTTGGAG GCACTGCCTGAGACCACA 
HoxA9 -15bp AACCGCTCTGGTATCCTT GGAGGGAGGGGAGTAACAA 
HoxA9 + 2kb CGGGTCTCCGCTCTACTC ATGGGTGCCTCTGGATCT 
HoxA9 +3.8 kb GCATCCCGGAGAACTATCT GGAGAGAAGCTGTGGCATAA 
HoxA9 +7.5kb AGCCCAGACCCAGTTTTT ACAGGAAACGGAGGAAACAA 
HoxA9 +8.5kb AAACCCGACTTCACAATGGA AGCCTGGACCCACTGAAA 
HoxA9 +5.6kb control  GCTCACACAAATCCCATTCCA CTTTCTCGCCGCCATCTC 
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CHAPTER 3.    RESULTS 
 
 
Downregulation of GATA2 Expression during Hematopoiesis in the Adult BM 
 
To monitor GATA2 expression during hematopoiesis we first isolated murine 
hematopoietic stem cells and various progenitor cells based on cell surface marker 
expression by FACS Sorting. The Kit
+
 Sca1
+
 Lin
-
 CD150
+
CD48
-
 population (SLAM) is 
highly enriched for Long Term HSCs (LT-HSCs) in which one in 2.1 cells (47%) yield 
long-term multilineage reconstitution in irradiated mice.
129
 The Kit
+
 Sca1
+
 Lin
- 
(LSK) 
population is a heterogeneous population of both short term reconstituting (ST-HSCs), 
long term reconstituting HSCs (LT-HSCs) and multipotent progenitors (MPPs). The Kit
+
 
Sca1
-
 Lin
- 
population is devoid of stem cell activity and can be fractionated into Common 
Myeloid Progenitor (CMP), Granulocyte Monocyte Progenitor (GMP) and 
Megakaryocyte Erythroid Progenitor (MEP).
130
 The Common Lymphoid Progenitor 
(CLP) is present in the Kit
low
 Sca1
low
 Lin
- 
CD127
+ 
population.
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 BM isolated from 10 
C57BL/6 mice was pooled and sorted into the populations described above and lysed for 
RNA (Figure 3-1A). Based on quantitative RT-PCR analysis we found that GATA2 
expression was highest in the LT-HSCs (Figure 3-1B). The heterogeneous LSK 
population had 1.5 fold lower expression than the LT-HSCs due to the presence of lower 
expressing ST-HSCs (Figure 3-1B). In the progenitor compartment GATA2 expression 
was downregulated more in the CLP (12 fold) than the myeloid progenitors (2.4-3.3 fold) 
(Figure 3-1B). The least expression was seen in the mature Lin 
+
 cells (20 fold) (Figure 
3-1B). In summary downregulation of GATA2 expression is seen during hematopoietic 
differentiation and myeloid progenitors have higher GATA2 expression than the 
lymphoid progenitors. 
 
 
GATA2-ERT Expressing BM Cells Exhibit TAM Independent GATA2 Function in 
CFU-C Assays  
 
Previous studies from our lab have demonstrated that bone marrow progenitors 
and stem cells subjected to enforced expression of GATA2 from a retroviral vector show 
a complete loss of colony forming activity in vitro and a loss of repopulating ability in 
vivo
95
. We developed an inducible GATA2-ERT vector in which the protein would be 
cytosolic in the absence of Tamoxifen (TAM) and with the addition of TAM enters into 
the nucleus thus allowing regulated GATA2 activity in response to Tamoxifen (Figure 
3-2A). The GATA2-ERT vector was first tested for TAM-induced reduction in colony 
forming activity. Bone marrow cells transduced with the MSCV GATA2 ires GFP and 
MSCV GATA2-ERT ires GFP vectors showed similar GATA2 expression at the mRNA 
level compared to the control MSCV ires GFP vector transduced and untransduced BM 
cells (Figure 3-2B). The transduced BM cells were then plated in methylcellulose media 
for colony assays in the presence or absence of 100 nM Tamoxifen. Consistent with our 
previous results, the proportion of GFP + colonies formed in the GATA2 group was 8 
fold lower than the control GFP group irrespective of the Tamoxifen treatment (Figure 
3-3A). GATA2-ERT transduced BM cells in the absence of Tamoxifen formed colonies 
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Figure 3-1. Endogenous GATA2 expression in various stem and progenitor 
compartments of the adult BM. 
(A) Pooled BM from 10 mice is depleted of lineage markers (Ter119, Gr1, Mac1, CD4, 
CD8, B220, and NK1.1) and then stained for progenitor and stem cell markers (Panel 1-
CD34, ckit, Sca1, FcγR and CD117; Panel 2 – ckit, Sca1, CD150, CD48). Detailed gating 
strategy used for sorting various compartments for subsequent RNA extraction is shown.  
(B) GATA2 expression levels in sorted stem and progenitor compartments relative to 
total BM using quantitative RT-PCR and TaqMan primer probe sets. GAPDH was used 
as the endogenous control.  
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Figure 3-2. Successful transduction of murine BM cells with the inducible 
GATA2-ERT retroviral vector. 
(A) Schematic of the MSCV based retroviral vectors used in the study (NF= N-terminus 
zinc finger, CF= C-terminus zinc finger). The vectors contain an internal ribosomal entry 
site (ires) that allows cap independent translation of the GFP coding sequence. Thus 
transgene GATA2-ERT dose in individual cells can be predicted based on GFP 
expression (Mean Fluorescence Intensity). The aminoacid sequences of the linker region 
connecting human GATA2 and the ERT in the MSCV GATA2-ERT vector is also 
shown. (B) Quantitative RT-PCR analysis of gene expression of total GATA2 (mouse & 
human) in lineage depleted BM cells 2 days post-transduction with the above vectors. 
GAPDH was used as the endogenous control. 
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Figure 3-3. GATA2-ERT expressing cells exhibit TAM independent GATA2 
function on myeloid CFU-C assays. 
(A) Bone marrow cells transduced with MSCV-iresGFP, MSCV-GATA2iresGFP and 
MSCV-GATA2-ERTires GFP vectors were plated in semisolid media (Methocult 
M3434) in the presence of 100 nM Tamoxifen or equivalent volume of Ethanol. 7 days 
later total and GFP +ve primary colonies were counted to calculate the percentage of GFP 
+ve CFU-C (n=3). (B) Representative images of primary colonies in the absence of 
Tamoxifen. (C)  CFU-Cs from MSCViresGFP and GATA2-ERTiresGFP and mock 
transduced BM cells were tested for serial replating ability (n=3). Total colonies were 
scored, harvested and re-plated every 7 days after plating. Cells were plated at 5X103 per 
plate in the primary plating followed by 2.5X104 per plate for secondary and tertiary 
plating respectively.  
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similar in number to the control GFP vector transduced cells. However, in the presence of 
100 nM Tamoxifen there was a 13-fold reduction in the GATA2-ERT colonies, an effect 
similar to the GATA2 vector.  Surprisingly the sizes of the GATA2-ERT colonies in the 
absence of Tamoxifen were consistently larger than the mock and control GFP vector 
colonies (Figure 3-3B). To test if this larger colony size is associated with increased 
self-renewal activity we tested the GATA2-ERT vector against the control vector in a 
serial colony replating assay. Cells harvested from primary colonies of GATA2-ERT 
transduced cells were able to consistently generate four-fold higher secondary colonies 
than the GFP transduced cells (Figure 3-3C). When replated for tertiary colonies, only 
the GATA2-ERT transduced cells retained cells with colony forming, clonogenic 
potential. 
 
 
GATA2-ERT Vector Immortalizes Primary BM Cells into Myeloid Cell Lines  
 
Given the effect of GATA-2ERT expression on endowing serial replating 
potential on hematopoietic progenitors, we next tested whether expression would have 
effects on cells propagated in vitro liquid cultures. Transduced BM cells were cultured in 
DMEM with 15% FBS in the presence of IL-3, IL-6 and SCF. Under these culture 
conditions normal untransduced BM cells cease to proliferate at 3- 4 weeks becoming 
mast cells.
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 GATA2-ERT transduced bone marrow cells showed greater proliferation 
compared to the GFP transduced and untransduced cells (Figure 3-4A) frequently 
resulting in the establishment of immortalized cell lines (6 out of 7 experiments). Wright 
Giemsa stains indicated that the GATA2-ERT immortalized cell lines were composed of 
immature myeloid cells with some spontaneous differentiation (Figure 3-4B). This was 
further confirmed by FACS analysis, which showed that the 50% of cells are Gr1+ 
Mac1+  in these cell lines compared to the controls which become mast cells expressing 
ckit+ FcER1+ (Figure 3-4C). Only once the control GFP vector immortalized BM cells 
(1 out of 7 experiments) resulting in a GFP cell line. All of these immortalized cell lines 
are IL-3 dependent (data not shown). Upon treatment with 100 nM of Tamoxifen all the 
GATA2-ERT cell lines stopped proliferating (Figure 3-5A) similar to the CFU-C assays. 
Cell cycle analysis showed cell cycle arrest with increased G0/G1 phase as early as 24 
hours post TAM treatment in GATA2-ERT cell lines (Figure 3-5B). Thus, in the 
presence of TAM, the GATA2-ERT vector behaves as a wild type GATA2.  
 
 
Low Nuclear Concentration Achieved by the GATA2-ERT Vector in the Absence of 
TAM 
 
The increased proliferation and colony forming ability of the GATA2-ERT vector 
in the absence of Tamoxifen could be the result of low levels of GATA2-ERT entering 
the nucleus which has been reported in other inducible vectors like mycER and 
creER.
133,134
 To test this hypothesis, subcellular protein fractionation was performed on 
untreated, Tamoxifen (100 nM) and Ethanol (vehicle) treated GATA2-ERT cell lines. 
GATA2-ERT protein was detected in both the nuclear and cytoplasmic fractions of 
untreated and vehicle treated cells confirming the activity of the GATA2-ERT vector in 
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Figure 3-4. GATA2-ERT immortalizes primary BM cells into myeloid cell lines. 
(A) Growth curves of lineage depleted BM cells transduced with MSCV-GATA2-
ERTiresGFP and MSCV-iresGFP vector compared with untransduced cells. Cells were 
counted at the time points indicated by trypan blue exclusion method. Results are shown 
as mean ± SD for 3 independent experiments. (B) Wright-Giemsa stained cytospin slides 
at day 27 under light microscopy. (C) FACS analysis at day 28 after staining for mast cell 
markers (c-kit, FcεRI) and myeloid markers (Gr-1, Mac-1).  
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Figure 3-5. Effects of the absence and presence of Tamoxifen on GATA2-ERT cell 
lines. 
(A) Growth curves of GATA2-ERT and GFP cell lines treated with 100 nM Tamoxifen 
(TAM) or an equivalent volume of Ethanol (EtOH). (B) Cell cycle analysis of GATA2-
ERT and GFP cell lines treated with 100 nM TAM or EtOH. At 24 and 48 hours post-
treatment cells are lysed with Propidium Iodide and analyzed by flow cytometry. Results 
are shown as mean ± SD of experiments on 3 different GATA2-ERT cell lines and 1 GFP 
cell line.  
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the absence of Tamoxifen (Figure 3-6A). Upon treatment with 100 nM Tamoxifen, 
GATA2-ERT protein was detected only in the nuclear fractions showing complete 
nuclear translocation. Thus GATA2-ERT translocation in the absence of Tamoxifen 
could achieve a low level tonic activity in the nucleus, 3-fold lower than with complete 
translocation with Tamoxifen as measured by densitometry analysis using ImageJ 
software. To independently confirm these results we also did immunostaining on 
untreated and TAM treated GATA2-ERT cell lines (Figure 3-6B) and retroviral 
packaging cells (Figure 3-7) followed by confocal imaging. In the absence of TAM both 
these cells showed nuclear GATA2-ERT protein staining which co-localized with DAPI. 
Upon TAM treatment, the intensity of the nuclear GATA2-ERT signals increased 
demonstrating further nuclear translocation. The cytoplasmic GATA2-ERT signals in the 
absence of TAM could only be visualized in the packaging cells but not in the GATA2-
ERT cell lines possibly due to the presence of thin cytoplasm in these cells. These data 
confirm the low nuclear concentration achieved by the GATA2-ERT vector in the 
absence of TAM. 
 
 
Distinct Progenitor and Mature Cell Populations Are Present in GATA2-ERT Cell 
Lines 
 
When GATA2-ERT cell lines and the randomly immortalized GFP cell lines were 
stained for c-kit and Gr-1 markers, three different populations were consistently observed 
(Figure 3-8A). These populations were named P1 (c-kit+Gr-1- ), P2 (c-kit-Gr-1- ) and P3 
(Gr-1+) respectively. Upon Wright- Giemsa staining P1 and P2 populations showed an 
immature phenotype with large nucleus and thin cytoplasm whereas the P3 population 
showed mature granulocytes with segmented nuclei (Figure 3-8B). When these 
populations were sorted from GATA2-ERT cell lines and then cultured for 7 days, the 
highest proliferation was observed in P1 followed by P2 and the lowest proliferation seen 
in P3 (Figure 3-8C) . In 7 days sorted P1 cells can generate P2 and P3, P2 cells can 
generate only P3 and finally P3 cells did not generate other populations (Figure 3-8A, D 
and E). Taken together, the above data show that GATA2-ERT cell lines are organized as 
a hierarchy with the progenitor P1 cells differentiating into an intermediate P2 cells and 
finally becoming the mature P3 cells. 
 
 
Myeloid Immortalization Is GATA2-ERT Dependent 
 
To confirm if the GATA2-ERT immortalized cell lines are indeed dependent 
upon the low level tonic GATA2 activity we examined the effects of GATA2-ERT 
knockdown in three independently immortalized GATA2-ERT cell lines. We used a 
mir30 based shRNA containing lentiviral vectors carrying m-cherry as a reporter (Figure 
3-9A). Because a single mRNA transcript is generated from the MSCV GATA2-ERT ires 
GFP vector for the production of both GATA2-ERT and GFP proteins we tested 
GATA2-ERT knockdown using a shRNA targeting GFP (shGFP). After transduction 
with shGFP vector, mcherry + ve transduced cells showed an 80% GATA2-ERT protein 
knockdown compared to mcherry –ve untransduced cells (Figure 3-9B). The shGFP 
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Figure 3-6. Subcellular localization of GATA2-ERT before and after treatment 
with TAM in GATA2-ERT immortalized cell lines. 
(A) Subcellular localization of GATA2-ERT protein in GATA2-ERT cell lines after 
treatment with 100 nM TAM or ethanol for 3 hours compared with untreated cells. 
Proteins from GATA2-ERT cell lines (WCL) were sub-fractionated into cytoplasmic 
(Cyto) and nuclear (Nuc) and western blotted for GATA2-ERT, GAPDH (cyto) and 
Lamin B (Nuc). GATA2-ERT protein was detected using an anti-ER antibody. (B) 
GATA2-ERT and GFP cell lines were attached retronectin coated coverslips in the 
presence of 100 nM TAM or EtOH for 12 hours then fixed and stained. Red represents 
GATA2-ERT (1°-αGATA2, 2°- α-rabbit Alexa Flour 555) and blue represents DAPI. 
Top row shows GATA2-ERT staining and bottom row shows an overlay with DAPI. 
Imaging was performed using Zeiss LSM 510 Meta point scanning confocal microscope 
with a Plan Apochromat 63X/1.4 Oil objective and zoom scan of 1.3.  
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Figure 3-7. Subcellular localization of GATA2-ERT in GPE-86 producer cells. 
GPE-86 GFP and GATA2-ERT cells were attached to Poly-D lysine coated glass bottom 
dishes overnight and then treated with 100 nM TAM/Ethanol for 24 hours before fix and 
stain. Red represents GATA2-ERT (1°-αGATA2, 2°- α-rabbit Texas Red) and blue 
represents DAPI. Top row shows GATA2-ERT staining and bottom row shows an 
overlay with DAPI. Imaging was performed using Nikon C1Si laser scanning confocal 
microscope with a Plan Apochromat 60.0X/1.45/.13 Oil objective.  
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Figure 3-8. Distinct progenitor and mature cell populations are present in 
GATA2-ERT cell lines. 
(A) Representative FACS Analysis of unsorted GATA2-ERT cell line and sorted P1, P2 
and P3 populations after 7 days in culture, showing the ability of the sorted populations to 
regenerate the starting cell line. (B) Wright Giemsa stains on cytopsins of sorted P1, P2, 
P3 populations and P3 population after 7 days in culture. (C) Growth curves of the sorted 
populations during the 7 days in culture. (D) Data from Figure 3-8A represented as bar 
graphs comparing the frequencies of different populations. (E) Data from a second 
experiment performed on another independently generated GATA2-ERT cell line 
showing the existence of a hierarchy.  
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Figure 3-9. GFP targeting vector effectively knocks down GATA2-ERT protein 
levels. 
(A) Schematic of the mir30 based lentiviral shRNA vector used in the study. MSCV 
promoter drives the mir30 based shRNA and PGK promoter drives the reporter mcherry 
expression. Location of the EcoRI and XhoI sites used for cloning 137bp hairpins is also 
shown. (B) GFP targeting vector effectively knocks down GATA2-ERT protein levels. 
Three GATA2-ERT cell lines and a GFP cell line were transduced with shRNA vectors 
targeting GFP sequence (shGFP) or a scrambled sequence (NS). 3 days post-transduction 
mcherry + and mcherry - cells were sorted and lysed for proteins and western blotted 
against GATA2-ERT (α-ER alpha), GAPDH and GFP.  
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vector transduced cells grew faster than untransduced cells in liquid culture as shown by 
a progressive reduction in m-cherry% in the shGFP group over an 18 day period (Figure 
3-10A and B). On the other hand when GATA2-ERT cells were transduced with the 
control non silencing vector (NS) both transduced and untransduced cells showed a 
similar GATA2-ERT protein expression (Figure 3-9B) and equal proliferation in liquid 
culture with a stable m-cherry% over an 18 day period (Figure 3-10A and B). When the 
GFP cell line with similar myeloid characteristics to the GATA2-ERT cells was 
transduced with the shGFP and NS vectors there were no changes in proliferation 
excluding other toxic effects of microRNA expression in myeloid cells (Figure 3-10A 
and B). To identify the nature of the growth defect associated with GATA2-ERT 
knockdown we looked at the cell cycle, cell death and differentiation of the GATA2-ERT 
cell lines after transduction with the shGFP vector. There was no increase in dead cells in 
these cultures based on trypan blue staining (data not shown). However cell cycle 
analysis using Hoechst staining showed a decrease in cycling cells after GATA2-ERT 
knockdown (Figure 3-11). This also correlated with the increase in P3 differentiated cells 
in these cultures (Figure 3-12A, B and C). These data demonstrate that expression of 
GATA2-ERT remains essential for self-renewal and proliferation of the myeloid 
progenitors after immortalization and loss of GATA2-ERT leads to their rapid 
differentiation into non-cycling ,Gr1 expressing, mature cells. 
 
 
Screening of Genes Involved in GATA2-ERT Mediated Immortalization  
 
Gene expression analysis was performed to identify genes differentially regulated 
between three independently generated GATA2-ERT cells lines compared to the GFP 
cell line which does not express GATA2. A total of 1861 probesets showed a greater than 
2-fold difference between each of the GATA2-ERT cell lines vs. the GFP cell line. 
Among them, 995 probesets were increased and 866 probesets were decreased. Estrogen 
receptor1 (Esr1) probeset was on the top of the list with a 500 fold average fold 
difference. Since the human GATA2 cDNA is fused to the estrogen receptor ligand 
binding domain in the vector we expected to see high expression of the Esr1 probeset. 
Gene ontology and pathway enrichment analysis was performed using DAVID 
bioinformatics databases. Differentially regulated genes were grouped into genes 
regulating cell proliferation (143 probsets, Table 3-1), hematopoiesis (57 probesets) and 
apoptosis (100 probestes). Top 10 upregulated and downregulated genes in these lists are 
shown in Tables 3-1, 3-2 and 3-3. Myeloid leukemia related genes like HoxA9, Nmyc 
and Bcl11a were found to be significantly up-regulated in the microarray. Real time PCR 
analysis using TaqMan primers confirmed that Nmyc was 50-fold up regulated and 
HoxA9 was 2400-fold up regulated in the GATA2-ERT cell lines (Figure 3-13A). 
 
 
HoxA9 and Nmyc Knockdown Partially Recapitulates GATA2-ERT Loss in 
Immortalized Cell Lines 
 
The knockdown approach described above was used to test if HoxA9 or Nmyc is 
required for GATA2-ERT mediated proliferation. The vectors designed for knockdown  
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Figure 3-10. Knockdown of GATA2-ERT inhibits proliferation of the 
immortalized cell lines. 
(A) GATA2-ERT knockdown inhibits proliferation of GATA2-ERT immortalized cell 
lines. FACS analysis of GFP and mcherry expression in GATA2-ERT and GFP cell lines 
transduced with shGFP and NS vectors at different time points in liquid culture. Cells 
were also stained with Hoechst for simultaneous cell cycle analysis. Transduction with 
shGFP vector results in a GFP low mcherry+ population (Quadrant 1) compared to GFP 
high mcherry+ (Quadrant 2) population in NS transduced cells. (B) Summary of the 
percentages of mcherry+ cells from above and 2 other GATA2-ERT cell lines.  
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Figure 3-11. Knockdown of GATA2-ERT inhibits proliferation of the 
immortalized cell lines due to G0/G1 cell cycle arrest. 
Cell cycle analysis using Hoechst was performed on GATA2-ERT cell lines (n=3) at 
day2 and day7 post transduction with the NS and shGFP targeting vectors. Cell cycle 
effects on GATA2-ERT cells transduced with shGFP (quadrant 1, Q1) were compared 
with NS transduced cells (quadrant 2, Q2) and untransduced cells (quadrant 3, Q3) in 
both groups. The location of the quadrants was shown in Figure 3-10A.  
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Figure 3-12. Knockdown of GATA2-ERT inhibits proliferation of the 
immortalized cell lines due to differentiation. 
(A) Representative FACS Plots of GATA2-ERT and GFP cell lines transduced with the 
non-silencing (NS) and GFP silencing (shGFP) shRNA vectors and Mock transduced 
cells 6 days post- transduction. (B) Summary of the frequencies of different populations 
from above and 2 other GATA2-ERT cell lines (n=3). (C) Frequencies of different 
populations from the above GFP cell line (n=1).    
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Table 3-1. Genes differentially expressed in GATA2-ERT vs. GFP cell line (cell 
proliferation). 
 
Gene Symbol Description Fold Change 
Esr1 estrogen receptor 1 (alpha) 500.3 
Mycn v-myc myelocytomatosis viral related oncogene, 
neuroblastoma derived (avian) 59.7 
Arrdc4 arrestin domain containing 4 20.2 
Cd28 CD28 antigen 17.5 
Il6st interleukin 6 signal transducer 16.0 
S1pr1 sphingosine-1-phosphate receptor 1 14.9 
Pawr PRKC, apoptosis, WT1, regulator 14.9 
Fgf6 fibroblast growth factor 6 9.6 
Trim24 tripartite motif-containing 24 9.2 
Sox2 SRY-box containing gene 2 9.0 
Tnfrsf9 tumor necrosis factor receptor superfamily, member 9 -20.2 
Mab21l1 mab-21-like 1 (C. elegans) -21.1 
Il2ra interleukin 2 receptor, alpha chain (probe 1) -22.1 
Tnfsf10 tumor necrosis factor (ligand) superfamily, member 10 -26.0 
Hes1 hairy and enhancer of split 1 (Drosophila) -28.5 
Angptl2 angiopoietin-like 2 -35.1 
Fgf3 fibroblast growth factor 3 -40.3 
Arnt2 aryl hydrocarbon receptor nuclear translocator 2 -45.3 
Il2ra interleukin 2 receptor, alpha chain (probe 2) -104.0 
Mab21l1 mab-21-like 1 (C. elegans) -165.0 
 
Individual Fold changes of genes differentially expressed in three GATA2-ERT cell lines 
compared to the GFP cell line. Differentially expressed genes involved in regulation of 
proliferation (GO: 0042127) were shortlisted using DAVID bioinformatics databases 
(http://david.abcc.ncifcrf.gov). Top 10 differentially regulated genes are represented 
above.  
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Table 3-2. Genes differentially expressed in GATA2-ERT vs. GFP cell line 
(hematopoiesis). 
 
Gene Symbol Description Fold Change 
Hoxa9 homeo box A9 77.0 
Bcl11a B-cell CLL/lymphoma 11A (zinc finger protein) 36.8 
Cd28 CD28 antigen 17.5 
Eomes eomesodermin homolog (Xenopus laevis) 11.3 
Hdac9 histone deacetylase 9 11.1 
Clcf1 cardiotrophin-like cytokine factor 1 8.4 
Ercc1 Excision repair cross-complementing rodent repair 
deficiency, complementation group 1 7.6 
Satb1 special AT-rich sequence binding protein 1 7.3 
Pbx1 pre B-cell leukemia transcription factor 1 7.3 
Tgfbr2 transforming growth factor, beta receptor II 5.8 
Themis thymocyte selection associated -6.8 
Card11 caspase recruitment domain family, member 11 -7.8 
Jag2 jagged 2 -7.8 
Gadd45g growth arrest and DNA-damage-inducible 45 gamma -8.4 
Xrcc5 
X-ray repair complementing defective repair in 
Chinese hamster cells 5 -11.8 
Kit kit oncogene -13.0 
Bcl6 B-cell leukemia/lymphoma 6 -14.9 
Cd74 
CD74 antigen (invariant polypeptide of major 
histocompatibility complex, class II antigen-associated) -17.5 
Hbb-b1 /// 
Hbb-b2 
hemoglobin, beta adult major chain /// hemoglobin, 
beta adult minor chain -26.6 
Hba-a1 /// 
Hba-a2 
hemoglobin alpha, adult chain 1 /// hemoglobin alpha, 
adult chain 2 
-30.6 
 
Individual Fold changes of genes differentially expressed in three GATA2-ERT cell lines 
compared to the GFP cell line. Differentially expressed genes involved in regulation of 
hematopoiesis (GO: 0030097) were shortlisted using DAVID bioinformatics databases 
(http://david.abcc.ncifcrf.gov). Top 10 differentially regulated genes are represented 
above.  
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Table 3-3. Genes differentially expressed in GATA2-ERT vs. GFP cell line 
(apoptosis). 
 
Gene Symbol Description Fold Change 
Esr1 estrogen receptor 1 (alpha) 500.3 
Cd28 CD28 antigen 17.5 
Itsn1 intersectin 1 (SH3 domain protein 1A) 10.3 
Uaca uveal autoantigen with coiled-coil domains and 
ankyrin repeats 
9.2 
Clu /// 
LOC100046120 
clusterin /// similar to clusterin 8.0 
Ercc1 Excision repair cross-complementing rodent repair 
deficiency, complementation group 1 
7.6 
Cln8 ceroid-lipofuscinosis, neuronal 8 7.3 
Kitl kit ligand 7.1 
Epha7 Eph receptor A7 6.6 
Mgmt O-6-methylguanine-DNA methyltransferase 6.3 
Tnfsf9 tumor necrosis factor (ligand) superfamily, member 9 -13.3 
Tnfrsf9 tumor necrosis factor receptor superfamily, member 9 -14.6 
Bcl6 B-cell leukemia/lymphoma 6 -14.9 
Btg2 B-cell translocation gene 2, anti-proliferative -14.9 
Cd74 CD74 antigen (invariant polypeptide of major 
histocompatibility complex, class II antigen-
associated) 
-17.5 
Tnfrsf9 tumor necrosis factor receptor superfamily, member 9 -20.2 
Tnfsf10 tumor necrosis factor (ligand) superfamily, member 
10 
-26.0 
Prnp prion protein -33.5 
Gzmb granzyme B -97.0 
Il2ra interleukin 2 receptor, alpha chain -104.0 
Id3 inhibitor of DNA binding 3 -143.7 
 
Individual Fold changes of genes differentially expressed in three GATA2-ERT cell lines 
compared to the GFP cell line. Differentially expressed genes involved in regulation of 
apoptosis (GO: 0042981) were shortlisted using DAVID bioinformatics databases 
(http://david.abcc.ncifcrf.gov). Top 10 differentially regulated genes are represented 
above.  
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Figure 3-13. HoxA9 and Nmyc knockdown partially recapitulates GATA2-ERT 
loss in immortalized cell lines. 
(A) Quantitative RT-PCR analysis of gene expression of Nmyc, hoxA9, endogenous (m) 
and total (m+h) GATA2 in GATA2-ERT cell lines (n=3) and GFP cell line (n=1).  Gene 
expression is first normalized to GAPDH and represented as a ratio between GATA2-
ERT and GFP cell lines. (B) and (C) GATA2-ERT cell line was transduced with shRNA 
vectors targeting Nmyc (shNmyc), hoxA9 (shHoxA9) and a scrambled sequence (NS). 3 
days post-transduction mcherry + cells were sorted for total RNA extraction followed by 
quantitative RT-PCR. Expression levels of Nmyc and hoxA9 after knockdown relative to 
the scrambled vector is shown. GAPDH was used as the endogenous control. (D) and (E) 
FACS Analysis of m-cherry percentages of GATA2-ERT cell lines transduced with the 
respective shRNA vectors at different time points in liquid culture.  
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of Nmyc and HoxA9 showed 60% knockdown efficiency in the GATA2-ERT cell lines 
(Figure 3-13B and C). The well characterized shGFP and NS vectors were now used as 
controls. GATA2-ERT cell lines were transduced with the knockdown vectors at a 
similar MOI (50%-80% m-cherry + cells) and grown in liquid culture for 3 weeks. As 
expected GATA2-ERT cells transduced with the shGFP vector show a significant growth 
disadvantage compared to the non-silencing vector (NS) in liquid culture. Upon 
GATA2-ERT knockdown there is a progressive decrease in the m-cherry % over the 
18-day culture period (Figure 3-13D). During this time period the non-silencing vector 
transduced cells showed no significant changes in m-cherry+ cells. Nmyc and HoxA9 
knockdown also resulted in a progressive decrease in m-cherry+ cells but at slower rate 
than the shGFP group. The m-cherry marking in the shNmyc group dropped slowly from 
75% on day 2  to 40% on day 18 compared to the shGFP group where it dropped quickly 
from 73% on day 2 to 10% on day 11 (Figure 3-13D). Similarly in another experiment 
the m-cherry marking in the shHoxA9 group dropped slowly from 50% on day 2 to 30% 
on day 21 compared to the shGFP group it dropped quickly from 57% on day 2 to 3% on 
day 12 (Figure 3-13E). These results show that Nmyc and HoxA9 at least have a partial 
role in GATA2-ERT mediated proliferation. The fact that the growth defects are not 
complete can be explained by the lack of complete Nmyc and HoxA9 knockdown by 
these vectors and also by compensation by other GATA2 targets.  
 
 
Absence of GATA2-ERT Chromatin Occupancy in the Nmyc and HoxA9 Locus 
 
Since Nmyc and HoxA9 have a partial role in GATA2-ERT mediated 
proliferation; chromatin immunoprecipitation (ChIP) assays were performed to test 
whether Nmyc and HoxA9 are direct targets of GATA2-ERT. Protein extraction from 
GATA2-ERT cell lines under various non-denaturing conditions with protease inhibitors 
resulted in the rapid proteolysis of the 83KD GATA2-ERT protein into smaller fragments 
between 27KD to 40KD detected by an ER specific antibody (Figure 3-14A). Only when 
the cells were lysed in denaturing conditions using Laemelli sample buffer could this 
degradation be prevented. Since the GATA2-ERT cell lines contain Gr1+ granulocytes it 
is possible that proteolytic enzymes in their granules could cleave GATA2-ERT protein 
during extraction. When the GATA2-ERT cells were sorted into Gr1+ and Gr1- 
populations the total GATA2-ERT protein expression was similar in all the population 
under denaturing conditions (Figure 3-14B). When the proteins were extracted under 
non-denaturing conditions we could see less proteolysis in the Gr1- population indicating 
that the enzymes in the mature Gr1+ fraction cause the degradation (Figure 3-14B). The 
degradation is even further reduced in the Gr1- cells when the cells were fixed with 
formaldehyde and chromatin extracted (Figure 3-14C). So we extracted chromatin from 
Gr1- GATA2-ERT cells and performed ChIP assays using a rabbit polyclonal antibody 
against GATA2 (H-116 Santa Cruz) and normal rabbit immunoglobulins (IgG). We did 
quantitative PCR on the immunoprecipitated DNA fragments using primers that amplify 
known GATA2 binding regions in the GATA2 locus. The -3.9 kb, -1.8 kb and -2.8 kb 
regions in the GATA2 locus were significantly enriched (25 fold, 9 fold and 6.5 fold) 
confirming that the H-116 antibody effectively immunoprecipitates the GATA2-ERT 
protein (Figure 3-15A). Inspection of the Nmyc and HoxA9 locus revealed several 
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Figure 3-14. Elimination of the mature Gr1+ population in the GATA2-ERT cell 
lines prevents protein degradation and improves yield. 
Western blots under denaturing conditions using anti-ER antibody to test GATA2-ERT 
protein degradation. Protein lysates were extracted from a G2ERT cell line under 
different conditions described. (A) Proteins were extracted from GATA2-ERT cell lines 
under non-denaturing conditions with reagents such as M-PER (Pierce #78501) and Cell 
Lysis Buffer (Cell Signaling # 9803) or denaturing conditions with Laemelli and beta-
mercaptoethanol in the presence of protease inhibitors (PI) and PMSF. GPE-86 Producer 
cells expressing GATA2-ERT (positive) and GFP (negative) vectors were used as 
controls. (B) Proteins were extracted from unsorted and sorted Gr1 positive (Gr1 pos) and 
negative (Gr1 neg) populations under denaturing (Laemelli) and non-denaturing (M-
PER) conditions. (C) Fixed and sonicated chromatin samples were prepared from 
unsorted and Gr negative populations were western blotted after reverse cross link.   
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Figure 3-15. Absence of GATA2-ERT chromatin occupancy in the Nmyc and 
HoxA9 loci. 
Quantitative Chromatin Immunoprecipitation (Chip) Analysis was performed to measure 
the GATA2-ERT occupancy in the GATA2 (A), Nmyc (B) and HoxA9 (C) loci in a 
GATA2-ERT cell line. The ChIP was performed using a rabbit polyclonal GATA2 
antibody (H-116, Santa Cruz) and as a negative control ChIP was also performed with 
isotype matched preimmune IgG (IgG). The locations of the GATA2 binding sites tested 
are indicated relative to the Transcriptional start site of the gene. The -1.8, -2.8 and -3.9 
GATA2 binding sites are previously reported GATA2 binding sites and were used as 
positive controls for the assay. The 1S and 1G alternate first exons of GATA2 and the 
brain specific promoter (necdin) are previously reported non-GATA2 binding sites. We 
also designed primers for a hoxA9 locus region which does not have WGATAR motif 
(control) as an additional negative control.  
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predicted GATA2 binding sites containing the consensus “WGATAR” sequence. In the 
Nmyc locus we designed primers to test the regions which have 2 palindromic GATA2 
sites together with E-Box motif (CANNTG) which is shown to have higher predictability 
of GATA2 binding. In the HoxA9 locus we tested all the 7 predicted GATA2 binding 
sites. Surprisingly there was no enrichment seen in any of the sites tested in the HoxA9 
and Nmyc locus (Figure 3-15B and C). These results indicate that HoxA9 and Nmyc are 
probably not direct targets of GATA2 but could be secondary or tertiary targets. It is also 
possible that GATA2 binds to distal regulatory elements such as enhancers to regulate 
Nmyc and HoxA9 expression. 
 
 
Lymphoid Block and Myeloid Expansion in Recipients of GATA2-ERT Transduced 
Cells  
 
The effects of the GATA2-ERT protein expression on murine hematopoiesis was 
studied by BM transplant studies. BM cells isolated from 5-FU treated mice were 
transduced with the GATA2-ERT and control GFP vector at similar MOI. The 
transduced cells were transplanted into lethally irradiated recipients in presence or 
absence of four fold excess of competing mock cells. At 12 weeks post-transplant GFP 
marking in the peripheral blood of recipients were analyzed by flow cytometry. 
Recipients of undiluted control GFP vector transduced cells show similar GFP marking in 
B220+ cells (58%±20), Thy1.2+ cells (58%±15) and Gr1+ myeloid cells (84%±17) 
(Figure 3-16). In contrast the undiluted GATA2-ERT recipients show a very low GFP 
marking in B220+ cells (8%±3) and Thy1.2+ cells (14%±1) with high marking in Gr1+ 
cells (91%±3).This data indicate that the GATA2-ERT expressing HSCs preferentially 
differentiate into myeloid cells. The GFP mean fluorescence intensity in the B220+ cells 
and Thy1.2+ cells of GATA2-ERT recipients were much lower than the myeloid cells 
indicating that the cells which escape the lymphoid block have very low GATA2-ERT 
expression) (data not shown). The recipients of the diluted GFP vector transduced cells 
showed the expected lower percentages of GFP marking in all lineages compared to the 
undiluted group (B-cells 6%±3, T-cells 15%±4, myeloid 28%±18). However the diluted 
GATA2-ERT group still showed higher GFP marking in Gr1+ myeloid cells (82%±6) 
even after four fold dilution with mock cells. None of the transplant animals developed 
leukemia. These results demonstrate that GATA2-ERT provides a competitive advantage 
to myeloid cells in addition to a block in lymphoid differentiation. 
 
 
GATA2-ERT Blocks the Lymphoid Development after Common Lymphoid 
Progenitors (CLPs) and also Expands the Granulocyte Monocyte Progenitors 
(GMPs) 
 
Having found that the GATA2-ERT expands myeloid cells and blocks lymphoid 
differentiation the question remained as to the stage at which GATA2-ERT exerts its 
effects in both lineages. To investigate this we used the GATA2-ERT transgenic mice 
which were generated by lentiviral transduction of murine blastocysts. The GATA2-ERT 
transgene carried in the mice is driven by the same MSCV promoter as the retroviral 
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Figure 3-16. Lymphoid block and myeloid expansion in recipients of GATA2-ERT 
transduced BM. 
FACS analysis of GFP percentages in B220 + cells, Thy 1.2 + cells and Gr1 + cells in 
peripheral blood of recipients 12 weeks post-transplant. Values are represented as Mean 
± S.D .Total numbers of recipients in each group is as follows , GFP group (n=2), 
GATA2-ERT group (n=6), GFP 1:4 group (n=7) and GATA2-ERT 1:4 group (n=10).  
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vector used previously in the transplant experiments. Southern blot analysis revealed the 
presence of 2 copies of the transgene (data not shown). Quite similar to the transplant 
results, these mice consistently showed high GFP% in the Gr1+ and Mac1+ cells and 
very low GFP% in the B220+ and CD3+ cells in their peripheral blood (Figure 3-17A). 
The stem and progenitor cell compartments from the GATA2-ERT transgenic mice bone 
marrow were analyzed for GFP expression. The Lin-Sca1+Kit+ (LSK) compartment had 
35% GFP + cells which indicated that the GATA2-ERT transgene was frequently 
inactivated by position-effect variegation during HSC specification (Figure 3-17A). 
Presence of GFP marking in the CLP (70%±17) in bone marrow and its absence  in 
mature B220+, CD4+ and CD8+ cells in peripheral blood suggested a post-CLP block. In 
the myeloid lineage there was a progressive increase in vector-expressing cells with 
differentiation. The GMPs showed higher GFP% (72%±6) compared to the CMPs 
(36%±4), suggesting that GATA2-ERT has a proliferative effect on the GMPs. To 
identify the block in T-cell development we tested the GFP marking in thymocytes of 
GATA2-ERT mice at different stages of differentiation. GFP + thymocytes were only 
detected at the earliest DN1 stage (19%±5) which is lower than that of the CLPs in the 
bone marrow (Figure 3-17B). These data suggest that T-cell development is blocked at a 
pre-thymic stage and the few GATA2-ERT expressing cells which seed the thymus 
remain in the DN1 stage. 
 
To understand the molecular mechanisms behind the GATA2-ERT mediated 
lymphoid block, global gene expression profiling of GATA2-ERT expressing and non-
expressing LSKs from transgenic mice was performed. Our analysis showed 157 probe 
sets were up-regulated and 190 probe sets were down-regulated in the GATA2-ERT 
expressing LSKs. Furthermore, Gene Set Enrichment Analysis showed down-regulation 
of B cell differentiation, B-cell receptor signaling, IL7 pathways and primary 
immunodeficiency related pathways (Figure 3-17C). Crucial regulators of lymphoid fate 
(Vpreb1, Ebf1, IL7R, Rag1, Dntt, Btla, Rag2, Lef1, and Tcf1) were significantly down-
regulated in the GATA2-ERT expressing LSKs (Table 3-4). 
 
 
DNA Binding Activity of GATA2-ERT Is Required for Myeloid Expansion and 
Lymphoid Block 
 
It was possible that the myeloid expansion and the lymphoid block could be 
attributed either to the low level transcriptional activity of the nuclear GATA2-ERT or to 
cytoplasmic GATA2-ERT titrating out transcription factors required for lymphoid fate 
choice (Ikaros, EBF, E2A and Mef2c) by protein-protein interactions. To clarify the 
contribution from these two different processes we developed DNA binding mutants of 
GATA2-ERT and tested them in functional assays to ascertain whether the phenotypic 
effects required DNA binding of GATA2-ERT. Two point mutations C352P and C370P 
were made in the cysteine residues of the 2nd zinc finger of GATA2 which is critical for 
DNA binding activity (Figure 3-18A and B). These mutations were designed based on 
previous studies to disrupt the structural integrity of this zinc finger and thereby abolish 
DNA binding activity.
74,135,136
 The C352P and C370P mutant proteins expressed at 
similar levels to the wildtype GATA2-ERT protein in transduced bone marrow cells  
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Figure 3-17. GATA2-ERT blocks lymphoid development after CLPs and also 
expands GMPs. 
(A) FACS analysis of GFP percentages in various lymphoid and myeloid progenitors and 
mature cells from GATA2-ERT transgenic mice BM and peripheral blood (n=3). LSK= 
Lineage-, Sca1+, c-Kit+; CLP = Lineage-, IL-7Rα+, Sca1 low, c-Kit low; CMP = 
Lineage-, Sca1-, c-Kit+, FcγR intermediate, CD34 intermediate; GMP = Lineage-, Sca1-, 
c-Kit+, FcγR high, CD34 high. (B) FACS Analysis of GFP percentages in thymocytes 
from GATA2-ERT transgenic mice at various stages of differentiation (n=6). DN1= CD4 
-, CD8 -, CD44 +, CD25 -; DN2= CD4 -, CD8 -, CD44 +, CD25 +; DN3= CD4 -, CD8 -, 
CD44 -, CD25 +; DN4= CD4 -, CD8 -, CD44 -, CD25 -. (C)  GSEA Analysis of gene 
expression profile between GFP – vs. GFP + LSK cells from BM of GATA2-ERT 
transgenic mice (n=3). For each experiment RNA is isolated from sorted GFP + or GFP – 
LSK cells derived from pooled BM (7 GATA2-ERT transgenic mice per experiment). 
Enrichment plots shown for selected down regulated gene sets identified by GSEA.  
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Table 3-4. Changes in gene expression in GATA2-ERT expressing LSKs. 
 
Gene Symbol Description Fold Change 
Vpreb1 pre-B lymphocyte gene 1 -13.74 
Igll1 immunoglobulin lambda-like polypeptide 1 -11.71 
Ebf1 early B-cell factor 1 -11.22 
Blnk B-cell linker -8.47 
Il7r interleukin 7 receptor -7.65 
Rag1 recombination activating gene 1 -7.63 
Vpreb3 pre-B lymphocyte gene 3 -5.62 
Dntt deoxynucleotidyltransferase, terminal -5.18 
Btla B and T lymphocyte associated -3.34 
Rag2 recombination activating gene 2 -3.22 
Igh-6 immunoglobulin heavy chain 6  -3.09 
Tcrg-V4 T-cell receptor gamma, variable 4 -2.74 
Lef1 lymphoid enhancer binding factor 1 -2.71 
Igj immunoglobulin joining chain -2.65 
Tcrg-V2 / Tcrg-V3 T-cell receptor gamma, variable 2 / variable 3 -2.39 
Tcf7 transcription factor 7, T-cell specific -2.23 
Hbb-b1 /// Hbb-b2 hemoglobin, beta adult major chain / minor chain 3.33 
Igf1 insulin-like growth factor 1 3.55 
Hmox1 heme oxygenase (decycling) 1 4.73 
Ear1 / 12 /2/ 3 eosinophil-associated, ribonuclease A family, 
member 1 / 12 / 2 / 3 
4.89 
Axl AXL receptor tyrosine kinase 5.00 
Spic Spi-C transcription factor (Spi-1/PU.1 related) 5.21 
Epx eosinophil peroxidase 5.34 
Hba-a1 /// Hba-a2 hemoglobin alpha, adult chain 1 / chain 2 6.21 
C1qc complement component 1, q C chain 10.63 
Mrc1 mannose receptor, C type 1 16.06 
C1qb complement component 1, q  beta polypeptide 16.78 
C1qa complement component 1, q  alpha polypeptide 20.52 
Vcam1 vascular cell adhesion molecule 1 28.75 
 
Individual Fold changes of genes differentially expressed in GFP + LSKs compared to 
GFP - LSKs (FDR<0.05 using LPE T-test) of GATA2-ERT transgenic mice.  
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Figure 3-18. Schematic of the mutant GATA2-ERT retroviral vectors. 
(A) Schematic of the GATA2-ERT retroviral vectors carrying the C352P and 
C370P point mutations. (B) Amino acid sequences of the C-terminal Zinc Finger with the 
locations of the point mutations. The four cysteine residues co-ordinating the zinc ion of 
the 2nd finger are marked in green.
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(Figure 3-19A). Both the mutants also leaked into the nucleus of transduced BM cells 
similar to the wildtype GATA2-ERT (Figure 3-19B). However the C352P and C370P 
mutants showed a loss of DNA binding activity to the consensus WGATAR motif in gel 
shift assay compared to wildtype GATA2-ERT (Figure 3-20). We then tested the 
biological effects of the loss of DNA binding of the C352P and C370P mutations. Lack 
of DNA binding activity abolished the growth advantage of GATA2-ERT transduced BM 
cells over mock cells in liquid culture. GATA2-ERT wild type, two mutants and control 
GFP transduced BM cells were diluted with mock cells to achieve around 25% GFP+ 
cells. After 12 days in culture the percentage of GFP+ ve cells in the GATA2-ERT group 
was 91%±6 compared to C352P and C370P mutants and GFP group which remained at 
32%±7.5 , 40%±10 and 38%±14 (Figure 3-21A). 
 
The C352P and C370P mutations also abolished the self-renewal capacity of 
GATA2-ERT in serial CFU-C assays. The cells harvested from the primary colonies of 
GATA2-ERT wild type group formed at least 7-fold higher secondary colonies than the 2 
mutants and the control GFP groups (Figure 3-21B). Finally to test if DNA binding is 
required for myeloid expansion and lymphoid block in vivo, transplant experiments were 
performed as described above with the C352P mutant. At 12 weeks post-transplant 
undiluted GATA2-ERT recipients showed low GFP marking in B220+ cells (25%) and 
CD3+ cells (50%) with high marking in Gr1+Mac1+ cells (94% ) when compared to the 
control undiluted GFP recipients showing uniform GFP marking in all three subsets 
(B220+ 76%, CD3+ 73%, Gr1+Mac1+ 84%) (Figure 3-22A). The GATA2-ERT 
recipients also showed higher GFP MFI in the myeloid cells compared to the lymphoid 
cells indicating that there exists a dose dependent lymphoid block and only low 
expressing B and T cells escape the block (Figure 3-22B and C). The undiluted C352P 
mutant group show higher GFP marking in B220+ cells (50% ) and CD3+ cells (46%) 
similar to the Gr1+ Mac1+ cells (75%) resembling the GFP groups (Figure 3-22A). The 
C352P recipients also show similar GFP MFI between the myeloid and lymphoid subsets 
which show that the dose dependent lymphoid block requires DNA binding activity 
(Figure 3-22B and C). However since the GFP percentage and MFI of CD3 + ve cells is 
similar between the GATA2-ERT and C352P groups it is still possible that the T-cell 
block is mediated by protein-protein interactions. Upon four-fold dilution with mock cells 
only the GATA2-ERT wild type maintained high GFP% in Gr1+ Mac1+ cells (62%) 
compared to the C352P (19%) and control GFP (34%) groups. This demonstrates that the 
DNA binding activity of the GATA2-ERT is also required for myeloid expansion in vivo. 
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Figure 3-19. Expression and subcellular localization of GATA2-ERT mutants in 
primary BM cells. 
Lin - BM cells were transduced with the wild-type and mutant GATA2-ERT vectors and 
control GFP vector at similar MOI. (A) At the 3 days post-transduction proteins were 
isolated and western blotted for GATA2-ERT (α ER alpha) and GAPDH. All the groups 
had similar GFP percentages (60% to 70%). (B) Immunostaining was also performed at 
the same time point post-transduction. Cells were attached to retronectin coated 
coverslips for 40 minutes before fix and stain.  Red represents GATA2-ERT (1°-αER 
alpha, 2°- α-rabbit Alexa Flour 555), blue represents DAPI and Green represents GFP. 
Imaging was performed using Zeiss LSM 510 Meta point scanning confocal microscope 
with a Plan Apochromat 63X/1.4 Oil objective and zoom scan of 3.0.  
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Figure 3-20. C352P and C370P are DNA binding defective mutants of GATA2. 
Electrophoretic Mobility Shift Assay (EMSA) of wild type and mutant GATA2 and 
GATA2-ERT proteins. GATA2 and GATA2-ERT proteins were synthesized from 
pCDNA3.1 expression vectors by in vitro transcription translation (TnT) and bound to 
P
32
 labeled mouse alpha globin promoter oligonucleotide (containing a GATA binding 
site) in the absence and presence of 500 fold unlabeled oligonucleotides (D). Position of 
free probe and protein DNA complexes containing GATA2 and GATA2-ERT proteins 
are indicated.  
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Figure 3-21. DNA binding activity of GATA2-ERT is required for myeloid 
expansion in vitro. 
(A) FACS Analysis of GFP percentages of transduced lineage depleted BM cells at 
different time points in liquid culture after transduction (n=3). Transduced cells were 
diluted at day0 with mock transduced cells to start at a uniform GFP percentage (25% to 
28%) in all samples. (B) Total CFU-Cs from primary and secondary colony plating of 
transduced lineage depleted BM cells. Cells were plated at 1.25X103 per plate in the 
primary plating followed by 2.5X104 per plate for secondary plating.  
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Figure 3-22. DNA binding activity of GATA2-ERT is required for myeloid 
expansion and lymphoid block in vivo. 
(A) FACS analysis of GFP percentages in B220 + cells, CD3 + cells and Gr1 + Mac1 +ve 
cells (myeloid) in peripheral blood of recipients 12 weeks post-transplant. Values are 
represented as Mean ± S.D of 10 recipients in each group. (B) Comparison of GFP 
expression between B220 + cells, CD3 + cells and Gr1+ Mac1+ cells (myeloid) in 
representative GFP, GATA2-ERT and C352P transplant recipients at 16 weeks post-
transplant. (C) GFP Mean Fluorescence Intensity (MFI) Ratios in myeloid cells against 
B220 + and CD3 + cells in GFP, GATA2-ERT and C352P transplant recipients at 16 
weeks post-transplant (n=10).  
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CHAPTER 4.    DISCUSSION 
 
 
GATA2 Dose and Lineage Commitment 
 
 In this study, using retroviral transduction of GATA2-ERT vector into BM stem 
and progenitor cells followed by transplantation, we show that nuclear concentrations of 
the transcription factor GATA2 differentially regulate the development of granulocytes, 
T-lymphocytes and B-lymphocytes. High nuclear concentrations of GATA2 resulted in 
granulocyte development whereas moderate and low concentrations resulted in T-
lymphocyte and B-lymphocyte differentiation respectively. This conclusion was made 
from the observation that in the peripheral blood of GATA2-ERT transplant recipients, 
highest GFP expression (as measured by the MFI) was seen in the Gr1+ Mac1+ 
granulocytes, followed by a moderate GFP expression in the CD3+ T-lymphocytes and 
lowest GFP expression in the B220+ B lymphocytes. 
 
 Since the retroviral vector is bi-cistronic in which GFP is linked to GATA2-ERT 
by the ires, GFP and GATA2-ERT are co-expressed at the mRNA level. In the myeloid 
GATA2-ERT cell lines, a correlation at the protein level was also confirmed. In the 
knockdown experiments on the GATA2-ERT cell lines, high GFP expression in the 
“Non-silencing group “was consistent with the high GATA2-ERT protein levels 
compared to the “shGFP” group in which low GFP expression was consistent with low 
GATA2-ERT protein levels.  
  
 Our findings have two possible explanations. In the first scenario, in a myelo-
lymphoid progenitor different doses of GATA2 results in different cell fates (Figure 
4-1A). Alternatively, the lymphoid and myeloid differentiation can be initiated at the 
same dose of GATA2 but in order to complete the differentiation GATA2 needs to be 
downregulated to different levels in the myeloid and lymphoid lineages (Figure 4-1B). I 
favor the second explanation for the following reasons. Firstly, in the GATA2-ERT 
transgenic mice there was no difference in the GFP expression between the CLP and 
CMP and the lymphoid block occurs only after the CLP and ETP. The high GFP 
expressing myeloid cells were also selected only after the GMP stage (data not shown). 
Secondly, the endogenous GATA2 expression is very high in the multipotent progenitors 
(LSK cells) and seems to decrease upon differentiation to both the CLP and CMP. Even 
though endogenous GATA2 expression in the CLP is lower than the CMP; this low 
expression is not maintained but is even further reduced upon differentiation to the 
mature cells.   
 
 The hypothesis that GATA2 needs to be down-regulated to different levels for 
multi-lineage differentiation also agrees with the previous report from our lab that 
enforced expression of GATA2 at the “HSC dose” leads to a complete block in multi-
lineage differentiation. In the previous study MSCV-GATA2iresGFP vector resulted in 
GATA2 expression similar to that of the Lin- Sca1+ HSCs.
95
 Endogenous GATA2 
expression is highest in the HSCs and since the vector maintained the HSC dose, these 
HSCs did not differentiate. The current MSCVGATA2-ERTires GFP vector achieves the 
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Figure 4-1. Models of GATA2 dose dependent lineage commitment. 
(A) Different doses of GATA2 results in different cell fates in a myelo-lymphoid 
progenitor (LMPP). (B) Both lymphoid and myeloid differentiation can be initiated at the 
same dose of GATA2 but in order to complete the differentiation GATA2 need to be 
downregulated to different levels in the myeloid and lymphoid lineages. CMP: Common 
Myeloid Progenitor, ETP: Early Thymic Progenitor, CLP: Common Lymphoid 
Progenitor, HSC: Hematopoietic Stem Cell.  
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same transgene mRNA expression, but achieves a much lower GATA2 nuclear protein 
levels due to the protein distribution between the nucleus and the cytoplasm. This 
resulted in normal multi-lineage differentiation and led to the identification of GATA2 
dose effects further downstream in different lineages. 
 
 In the erythroid lineage GATA2 down regulation is mediated by GATA1. 
GATA1 is highly expressed in erythro-megakaryocytic lineages, whereas it is suppressed 
in HSCs and progenitor cell fractions.
130
 During erythroid differentiation GATA1 binds 
to regulatory elements in the GATA2 locus by displacing GATA2. This phenomenon 
called “GATA switch” results in down regulation of GATA2.87 The factors involved in 
GATA2 down regulation during myeloid and lymphoid differentiation still remain to be 
identified. 
 
 Dose dependent activity of transcription factors has been previously reported in 
normal hematopoiesis and leukemia.
137
 Best studied is the transcription factor PU.1. 
When Pu.1
-/-
 fetal liver hematopoietic progenitors were transduced with retroviral vector 
carrying PU.1 –GFP, the rescued Pro B-cells and macrophages had high and low GFP 
expression respectively.
46
 The authors showed that low PU.1 protein is associated with a 
B lymphoid fate and a high PU.1 protein was associated with a macrophage fate.  
 
 Gradual decrease in GATA2 expression show that the HSC transcription program 
does not terminate abruptly during differentiation but persists during many stages. 
Myeloid lineage may be more permissive to the HSC program than the lymphoid lineage. 
This can explain the lower GATA2 threshold in the lymphoid lineage compared to the 
myeloid lineage. 
 
 
GATA2 and HSC Quiescence 
 
 The HSCs remain highly quiescent compared to the progenitor cells which have 
prodigious proliferative capacity. Detailed cell cycle analysis and BrDU labeling assays 
revealed that most of the HSCs are non-dividing with only 1-3% in cycle and 
approximately 90% in G0 phase.
11,138,139
 A quiescent HSC population that divides only 5 
times during the lifespan of the mice was also demonstrated.
140
 Quiescence has been 
postulated to prevent stem cell exhaustion and is thought to protect stem cells from 
acquiring mutations leading to their malignant transformation to putative cancer stem 
cells.  
 
 Several components of the cell cycle machinery like cyclin dependent kinase 
inhibitors (p21, p27, p16 and p18), D type cyclins and their associated kinases (Cdk4 and 
Cdk6) have been shown to be critical for HSC quiescence.
141
 However the transcriptional 
control of these components of cell cycle machinery still remains to be elucidated. Our 
data show that GATA2 inhibits cell cycle in BM cells in a dose-dependent manner. In the 
GATA2-ERT cell lines we observe a higher nuclear concentration in the presence of 
TAM and a lower nuclear concentration in the absence of TAM. This high GATA2 
concentration resulted in a cell cycle arrest at G0/G1 phase. Similarly in CFU-C assays, 
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in the presence of TAM there is no colony formation and in the absence of TAM there is 
an increased self-renewal of CFU-C forming progenitors 
 
 Our data is consistent with the previous studies with GATA2-ER vectors. When 
GATA2-ER was expressed in hematopoietic cell lines (FDCP Mix, BaF3 and 32D) and 
primary murine BM cells and Sca+ Lin- progenitors it resulted in a ligand induced block 
in proliferation and cell cycle arrest.
106,142
 The GATA2-ERT mediated quiescence in 
BaF3 cells was shown to be reversible upon removal of Tamoxifen.
96
 High expression of 
GATA2 is associated with quiescence in both human and mouse HSCs. Two fold higher 
GATA2 expression was found in quiescent compared to cycling CD34+ CD38- human 
cord blood HSCs.
96
 Higher GATA2 expression was found in the quiescent adult mouse 
BM HSCs compared to the cycling fetal liver HSCs.
143
 GATA2 expression was 
progressively down-regulated when the adult BM HSCs were induced to cycle after 5-FU 
treatment and returned to normal when the quiescence was reset.
143
 All these data 
strongly suggest that GATA2 could mediate HSC quiescence in a dose dependent 
manner. 
 
 
GATA2 Mediated Myeloid Expansion 
 
 Persistent GATA2 expression not only favors a granulocyte cell fate choice but it 
also expands myeloid cells. GATA2-ERT expressing BM cells effectively out-compete 
mock transduced cells under myeloid conditions in vitro. In competitive transplant 
experiments, GATA2-ERT expressing cells also effectively out-compete mock 
transduced cells in the myeloid compartment. Even after transplanting GATA2-ERT 
expressing BM cells at 1:4 dilutions with mock cells, the recipients had an 82% GFP 
marked Gr1+ Mac1+ granulocytes. 
 
 The myeloid expansion is due to GATA2-ERT mediated increased self-renewal of 
the myeloid progenitors. In myeloid CFU-C assays, GATA2-ERT expressing myeloid 
progenitors formed larger size colonies which can further form colonies upon serial 
replating. This increased ability to form secondary colonies is a sign of increased self-
renewal. The myeloid progenitor that acquired increased self-renewal is probably the 
Granulocyte Monocyte Progenitor (GMP).This agrees with the observation that myeloid 
expansion in the GATA2-ERT transgenic mice starts at the GMP stage. This is also 
consistent with the previous reports that GATA2
+/-
 BM have reduced cellularity in the 
GMP compartment and formed reduced GM colonies in CFU-C assays.
144
  
 
 It is also possible that the increased self-renewal of myeloid progenitors by 
retroviral transduction of MSCV GATA2-ERTires GFP vector can be due to “insertional 
mutagenesis”.  Insertion of a gamma retrovirus neighboring an oncogene can be followed 
by its aberrant expression due to the enhancer effects of the viral LTR elements. 
Alternatively the insertion of the gamma retrovirus can also disrupt and inactivate a 
tumor suppressor gene. Both these effects can cause myeloid expansion independent of 
GATA2-ERT. However loss of GATA2-ERT in the GATA2-ERT transduced cell lines 
leads to loss of the self-renewing Gr1 negative progenitor population. This is followed by 
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complete differentiation into mature Gr1 positive cells and loss of proliferation in these 
cell lines. These data suggests that GATA2-ERT expression is essential for the continued 
proliferation and self-renewal of the myeloid progenitors and also that GATA2-ERT 
plays a direct role in these effects. It still remains possible that GATA2-ERT could exert 
these effects in co-operation with an un-identified gene which was insertionaly 
mutagenized. However GATA2-ERT vector immortalizes BM cells at a very high 
frequency than the GFP vector in vitro and also expands myeloid cells consistently in all 
transplant recipients. It is unlikely that the GATA2-ERT vector integrates next to the 
same co-operating gene in multiple experiments further arguing that these effects are 
mediated by GATA2-ERT alone. 
 
 Requirement of high expression of Nmyc and HoxA9 in the GATA2-ERT cell 
lines suggest that Nmyc and hoxA9 could be potential GATA2 targets in myeloid 
progenitors. Enforced expression of Nmyc by itself increased the proliferation and self-
renewal of myeloid progenitors.
145
 These effects were thought to be mediated by down-
regulation of TGF-β signaling, upregulation of Smad7 and JNK signaling pathways.145 
However these pathways were not affected by GATA2-ERT mediated Nmyc 
overexpression suggesting that the mechanism of Nmyc action could be different in the 
context of GATA2. Overexpression of HoxA9 is common in human mixed lineage 
leukemia (MLL) and is required for MLL fusion protein mediated transformation in a 
murine bone marrow transduction/transplantation model.
146,147
 Overexpression of HoxA9 
in the BM cells expands myeloid cells with a block in lymphoid development at the Pre-
B cell stage.
148
 Overexpression of HoxA9 also immortalized BM cells into GM-CSF 
dependent pro-myelocyte cell lines.
149
 Since the GATA2-ERT induced myeloid 
expansion is dependent on its DNA binding activity, GATA2-ERT could possibly bind to 
both Nmyc and HoxA9 locus resulting in their up-regulation. However the absence of 
GATA2-ERT chromatin occupancy in both the Nmyc and HoxA9 locus suggests that 
both Nmyc and HoxA9 could both be secondary targets of GATA2. Alternatively 
GATA2 could still bind to distant regulatory elements in the Nmyc and HoxA9 locus 
which were not tested in the ChIP assay. Such distal binding sites could be identified by 
performing ChIP-Seq analysis. 
 
 
GATA2 Mediated Lymphoid Block 
 
 Gene expression analysis on various hematopoietic stem and progenitor 
populations has shown a low promiscuous expression of genes from different lineages 
that the multipotent cell can potentially differentiate into.
150-152
 This process is called 
“Lineage Priming”. For example both lymphoid and myeloid specific genes were 
expressed in a Lympho-myeloid progenitor (LMPP) and both T-cell and B-cell lineage 
genes were expressed in a CLP. This is thought to be a consequence of alterations in 
chromatin structure which allows accessibility to various transcriptional regulators. This 
could also be due to the simultaneous expression of TFs of the respective conflicting 
lineages being expressed at low doses. 
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 Loss of lymphoid lineage priming in the MPPs has been associated with a block 
in lymphoid differentiation in a few gene knockouts. Ikaros knockout mice show an 
absence in B-cell development and T-cell defects. Ikaros had been shown to be essential 
for priming of lymphoid genes throughout the lymphoid differentiation starting from the 
HSC.
153
 One mechanism is thought to be chromatin remodeling because Ikaros interacts 
with the Nucleosome remodeling complex (NuRD).
154
 Recently it has been shown that 
Ikaros needs to interact with the GATA family of transcription factors and Cdk9 protein 
for appropriate chromatin binding and activation of its target genes.
155
 Ikaros was shown 
to interact with GATA2 in hematopoietic progenitors, GATA1 in erythroid cells and 
GATA3 in lymphoid cells. One mechanism by the sustained GATA2 expression in the 
MPPs and/or CLP can prevent Ikaros GATA3 binding thereby preventing Ikaros 
mediated lymphoid priming. Other gene knockouts which can cause lymphoid priming 
defects in the MPPs are Mef2c and E2A.
156,157
 Both Mef2ca and E2A are required for 
lymphoid differentiation. 
 
 Gene expression analysis on GATA2-ERT expressing MPPs show a 
downregulation of lymphoid specific signaling (IL7R), transcription factors 
(Ebf1,Lef1,Tcf7) and effectors (Rag1,Rag2,Dntt,Btla,Vpreb1 ,Igh-6,Tcrg ). There was a 
considerable overlap of genes downregulated in the Mef2c
-/-
 MPPs and GATA2-ERT 
expressing MPPs and that were E2A or EBF targets (Rag1, Dntt, Igh-6 and Tcf7).
157
 We 
hypothesize that sustained expression of GATA2 could antagonize the activity of 
transcription factors E2A, Mef2c and EBF to prevent lymphoid priming in the MPPs. 
Since the block in B-cell differentiation mediated by GATA2-ERT is dependent on its 
DNA binding activity, it is possible that GATA2 could bind to these lymphoid specific 
genes loci and prevent their transcription. GATA2 could additionally prevent the binding 
of other lymphoid specific TFs at these loci.  
 
 It is not clear whether the T-cell block is due to DNA binding activity of 
GATA2.The C352P transplant recipients showed similar GFP marking in T-cells 
compared to the wild type GATA2-ERT recipients. However the T-cell GFP marking 
approximates the myeloid GFP marking in the C352P recipients than the wildtype 
GATA2-ERT recipients. It is possible that titration of a T-cell lineage specific TF by 
GATA2-ERT in the cytoplasm due to protein-protein interaction can lead to the T-
lymphoid block. The lymphoid priming of such TFs will possibly be unaffected by 
GATA2-ERT. Some of the lymphoid specific transcription factors like Ikaros, GATA3 
and Ets1 were not differentially regulated in the MPP and could be potential candidates in 
this context.   
 
 
GATA2 Overexpression in Acute Myeloid Leukemia (AML) 
 
 GATA2 overexpression is frequently observed in Acute Myeloid Leukemia. In a 
recent study with a large series of AML patients GATA2 was overexpressed in 37.4% of 
cases (97/259) as measured by real-time RT-PCR.
158
 GATA2 overexpression was also 
significantly associated with FLT3-ITD and NPM1 mutations and overexpression of 
WT1 and Evi1.
158
 In another study with pediatric AML patients GATA2 was 
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overexpressed in 65% of cases (155/237).
159
 During complete remission GATA2 
expression returned to normal but remained high in patients with resistant disease.
159
 
GATA2 overexpression also correlated with a poor prognosis in patients receiving 
chemotherapy in both studies. GATA2 overexpression could possibly transform a normal 
myeloid progenitor cell like CMP or GMP into a Leukemic Stem cell (LSC) by 
conferring high proliferation and self-renewal capacity and also leading to additional 
mutations. Alternatively GATA2 overexpression can be a part of gene expression 
program inherited from a HSC which was transformed into a LSC by a different driver 
mutation. 
 
 Expression of many leukemic gene fusions like MLL-ENL, MLL-AF9, MOZ-
TIF2 and NUP98-HOXA9 can cause increased self-renewal of myeloid progenitors, 
immortalization of primary BM cells in vitro, and leukemia formation upon 
transplantation.
160-164
 In our study expression of GATA2-ERT immortalized primary BM 
cells into IL-3 dependent myeloid cell lines. GATA2-ERT expression also increased the 
self-renewal and proliferation of myeloid progenitors. However no leukemia was 
observed upon transplantation. The GATA2-ERT transgenic mice even when crossed 
with p16/p18 dko mice or p21/p27 dko did not show an increase in incidence of leukemia 
generation. These data suggest that additional cooperating mutations that can block 
differentiation may be required to transform GATA2-ERT expressing myeloid 
progenitors into LSCs. 
 
 Targeting the GATA2 mediated transcriptional network in the LSCs could be a 
potential strategy in AML treatment. In our studies knockdown of GATA2-ERT and its 
targets hoxA9 and Nmyc, in the immortalized cell lines differentiated these cells and 
stopped their proliferation. It will be interesting to test if patient derived AML cell lines 
are dependent on GATA2 for their proliferation. Such a strategy was employed in Ras 
oncogene driven Non-small cell lung cancers (NSCLC) which required GATA2 for their 
survival.
165
 GATA2 was found to transcriptionally regulate NFκB, proteasome and Rho 
signaling pathways and targeting these pathways reduced tumor development in lung.
165
 
In our gene expression studies on GATA2-ERT cell lines we did not identify these 
pathways suggesting that mechanisms could be different in hematopoietic neoplasms.  
 
 
GATA2 Mutations in Familial AML/MDS Syndromes 
 
 Mutations in GATA2 have been identified recently in rare familial disorders like 
DCML, MonoMAC syndrome and Emberger syndrome all of which have a 
predisposition to MDS and AML.
119-121
 DCML and MonoMAC syndromes are closely 
related syndromes characterized by monocytopenias, B-cell and NK cell lymphopenias 
associated with mycobacterial, fungal and viral infections and predisposition to 
MDS/AML.
166,167
 Emberger syndrome is characterized with severe lymphedema in 
addition to predisposition to MDS and AML.GATA2 mutations were also associated with 
familial MDS/AML syndromes without any other hematopoietic and vascular defects.
118
 
All these syndromes show an autosomal dominant inheritance with incomplete 
penetrance.  
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 Mutations of GATA2 found in these syndromes are highly heterogeneous ranging 
from deletions, frame-shift mutations leading to premature termination and point 
mutations. Since one wild-type allele was always present, some of the mutations 
(deletions and frame-shift) were thought to result in GATA2 haplo-insufficiency and lead 
to the disease. However in the case of point mutations the question remained whether the 
mutation could be dominant negative rather than a loss of function. Almost all of the 
point mutations were found in the 2
nd
 zinc finger domain which is important for DNA 
binding of GATA2 and protein-protein interactions. The Thr354Met and Thr355Del 
mutations both showed loss of DNA binding activity in gel shift and luciferase assays.
118
 
Surprisingly Thr354Met showed some dominant negative effects in ATRA induced 
differentiation of HL-60 cells.
118
 
 
 In our study we artificially designed two GATA2 DNA binding mutants (C352P 
and C370P) with mutations in the 2
nd
 zinc finger. Both these mutants abolished the 
myeloid expansion and lymphoid block mediated by sustained GATA2 expression. These 
results favor the hypothesis that the 2
nd
 zinc finger missense mutations found in patients 
are probably loss of function mutations and the disease is caused by GATA2 haplo-
insufficiency. GATA2
+/-
 mice are viable but have “smaller HSC pool size” due to defects 
in HSC specification.
91
 Under stress conditions like infections, due to enormous 
requirement of mature cells, there can be a HSC exhaustion leading to MDS and finally 
AML.  
 
 In our study the sustained GATA2 expression leads to B-cell specific block. This 
block is not associated with monocytopenia but rather an expansion of Gr-1+, mac1+ 
cells. In contrast in the DCML and MonoMAC syndromes the B-cell deficiency is 
associated with deficiency of CD14+ monocytes and NK cells. This suggest that the 
mechanism of B-cell block in DCML and MonoMAC is probably not sustained GATA2 
expression in CLP but a GATA2 haplo-insufficient HSC under stress generating less 
mature cells. BM analysis of MonoMAC patients also showed absence of multi-lymphoid 
progenitors and GMPs confirming this hypothesis.
166
  
 
 
Technical Considerations in Using the GATA2-ERT System 
 
 In the absence of TAM, GATA2-ERT protein is localized in both the nuclear and 
cytoplasmic fractions of BM cells. The leaky nature of the GATA2-ERT protein calls for 
two explanations for the observed phenotype. DNA binding and transcriptional regulation 
by the GATA2-ERT leaking into the nucleus or the retention of other factors by the 
cytoplasmic GATA2-ERT. To distinguish between these two mechanisms we used the 
DNA binding GATA2-ERT mutants, C352P and C370P. These two mutations were made 
in the cysteine residues of 2nd zinc finger domain of GATA2. The C352P was used 
previously by other groups to study functions of both GATA1 and GATA2.
74,135,136
 The 
myeloid expansion in vitro (CFU-C replating assay and proliferation assay) and in vivo 
(competitive transplants) were completely dependent on DNA binding of the leaky 
GATA2-ERT. The B lymphoid block was also dependent on DNA binding activity of 
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GATA2-ERT. On the other hand it is unclear whether T-cell block is due to DNA 
binding activity or protein-protein interactions. 
 
 The GATA2-ERT system we used contains a human GATA2 cDNA that was 
overexpressed in mouse hematopoietic tissues. Both human and mouse GATA2 are 480 
amino acids long with 98% similarity in amino acid composition. None of the amino acid 
changes are located it the critical zinc finger domains suggesting that both the mouse and 
human GATA2 probably behaves similarly in functional assays. In the GATA2-ERT 
transgenic mice, the developing immune system should recognize the human GATA2 
protein as self-protein and do not develop antibodies against it. Similarly the transplant 
recipients should also tolerate human GATA2 expressing BM cells since they received 
immune ablation before transplant.  
 
 Even though the GATA2-ERT system is advantageous because it achieved low 
doses of GATA2, the system has some drawbacks. It is possible that the GATA2-ERT 
fusion protein can have a different DNA binding and transactivation properties than the 
wild-type GATA2. GATA2-ERT may not fit easily into mult-protein complexes due to 
the presence of the extra ERT domain. However in functional assays, GATA2-ERT in 
presence of Tamoxifen completely blocked CFU-C colony formation an effect similar to 
the wild-type GATA2. This shows that minor differences in protein structure are 
tolerated in vivo. It will also be interesting to test if the effects of MSCV-GATA2-ERT 
vector can be replicated when wild-type GATA2 is driven from a weak promoter or an 
inducible promoter (Tet-Off systems). 
 
 
Future Directions 
 
 Using the GATA2-ERT system we presented evidence that GATA2 
overexpression confers increased self-renewal of myeloid progenitors and that lower dose 
of GATA2 is critical for this phenotype. To overcome the drawbacks of the ERT fusion 
system we need to confirm if this effect can be replicated when wild-type GATA2 is 
driven from a weak promoter or a tetracycline inducible promoter. Identification of 
GATA2 targets that mediate the self-renewal effect is important for development of AML 
therapy and also HSC expansion protocols. The mechanism by which GATA2 regulates 
Nmyc and HoxA9 potential targets in our study can be addressed by ChIP-Seq 
experiments on the GATA2-ERT cell lines.  
 
 Our studies show that GATA2 overexpression by itself is insufficient to initiate 
leukemia in transplant and transgenic animals. It will be interesting to test if Flt3-ITD or 
NPM1 mutations can co-operate with GATA2 overexpression to initiate leukemia. It is 
unclear how GATA2 is overexpressed in AML. Possible mechanisms could be 
translocations near GATA2 locus, epigenetic modifications or activation by an upstream 
regulator of GATA2. 
 
 Down regulation of GATA2 is a critical step for the multi-lineage differentiation 
of HSCs. Our data show that dysregulation of this process can lead to lymphoid block 
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and myeloid expansion. Identification of factors that down regulate GATA2 in various 
lineages is crucial for our understanding of hematopoiesis. In the erythroid lineage the 
transcription factor GATA1 has been shown to down regulate GATA2 by transcriptional 
repression.
98
  It will be important to identify the factors that down regulate GATA2 in 
myeloid and lymphoid lineages. 
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